The	O
α	B-GP
-	I-GP
melanocyte	I-GP
stimulating	I-GP
hormone	I-GP
/	O
peroxisome	B-GP
proliferator	I-GP
activated	I-GP
receptor	I-GP
-	I-GP
γ	I-GP
pathway	O
down	O
-	O
regulates	O
proliferation	O
in	O
melanoma	B-DS
cell	O
lines	O

Background	O

The	O
α	B-GP
-	I-GP
Melanocyte	I-GP
Stimulating	I-GP
Hormone	I-GP
(	O
αMSH	B-GP
)/	O
Melanocortin	B-GP
-	I-GP
1	I-GP
receptor	I-GP
(	O
MC1R	B-GP
)	O
interaction	O
promotes	O
melanogenesis	O
through	O
the	O
cAMP	O
/	O
PKA	B-GP
pathway	O
.	O

The	O
direct	O
induction	O
of	O
this	O
pathway	O
by	O
Forskolin	O
(	O
FSK	O
)	O
is	O
also	O
known	O
to	O
enhance	O
melanocyte	O
proliferation	O
.	O
αMSH	B-GP
acts	O
as	O
a	O
mitogenic	O
agent	O
in	O
melanocytes	O
and	O
its	O
effect	O
on	O
proliferation	O
of	O
melanoma	B-DS
cells	O
is	O
less	O
known	O
.	O

We	O
previously	O
identified	O
the	O
αMSH	B-GP
/	O
Peroxisome	B-GP
Proliferator	I-GP
Activated	I-GP
Receptor	I-GP
(	O
PPARγ	B-GP
)	O
pathway	O
as	O
a	O
new	O
pathway	O
on	O
the	O
B16	O
-	O
F10	O
mouse	B-OG
melanoma	B-DS
cell	O
line	O
.	O
αMSH	B-GP
induced	O
the	O
translocation	O
of	O
PPARγ	B-GP
into	O
the	O
nucleus	O
as	O
an	O
active	O
transcription	B-GP
factor	I-GP
.	O

This	O
effect	O
was	O
independent	O
of	O
the	O
cAMP	O
/	O
PKA	B-GP
pathway	O
and	O
was	O
mediated	O
by	O
the	O
activation	O
of	O
the	O
PI	O
(	O
4	O
,	O
5	O
)	O
P2	O
/	O
PLC	B-GP
pathway	O
,	O
a	O
pathway	O
which	O
we	O
have	O
described	O
to	O
be	O
triggered	O
by	O
the	O
αMSH	B-GP
-	O
dependent	O
MC1R	B-GP
stimulation	O
.	O

Moreover	O
,	O
in	O
the	O
same	O
study	O
,	O
preliminary	O
experiments	O
showed	O
that	O
mouse	B-OG
melanoma	B-DS
cells	O
responded	O
to	O
αMSH	B-GP
by	O
reducing	O
proliferation	O
and	O
that	O
PPARγ	B-GP
was	O
involved	O
in	O
this	O
effect	O
.	O

Due	O
to	O
its	O
key	O
role	O
in	O
the	O
control	O
of	O
cell	O
proliferation	O
,	O
PPARγ	B-GP
agonists	O
are	O
used	O
in	O
therapeutic	O
models	O
for	O
different	O
forms	O
of	O
cancer	B-DS
,	O
including	O
melanoma	B-DS
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
:	O
(	O
a	O
)	O
to	O
confirm	O
the	O
different	O
proliferative	O
behavior	O
in	O
response	O
to	O
αMSH	B-GP
in	O
healthy	O
and	O
in	O
melanoma	B-DS
condition	O
;	O
(	O
b	O
)	O
to	O
verify	O
whether	O
the	O
cAMP	O
/	O
PKA	B-GP
pathway	O
and	O
the	O
PLC	B-GP
/	O
PPARγ	B-GP
pathway	O
could	O
exert	O
an	O
antagonistic	O
function	O
in	O
the	O
control	O
of	O
proliferation	O
;	O
(	O
c	O
)	O
to	O
deepen	O
the	O
knowledge	O
of	O
the	O
molecular	O
basis	O
responsible	O
for	O
the	O
down	O
-	O
proliferative	O
response	O
of	O
melanoma	B-DS
cells	O
after	O
exposure	O
to	O
αMSH	B-GP
.	O

Methods	O

We	O
employed	O
B16	O
-	O
F10	O
cell	O
line	O
,	O
a	O
human	B-OG
melanoma	B-DS
cell	O
line	O
(	O
Mel	O
13	O
)	O
and	O
two	O
primary	O
cultures	O
of	O
human	B-OG
melanocytes	O
(	O
NHM	O
1	O
and	O
NHM	O
2	O
,	O
respectively	O
),	O
all	O
expressing	O
a	O
wild	O
type	O
MC1R	B-GP
and	O
responding	O
to	O
the	O
αMSH	B-GP
in	O
terms	O
of	O
pigmentation	O
.	O

We	O
evaluated	O
cell	O
proliferation	O
through	O
:	O
a	O
)	O
cell	O
counting	O
,	O
b	O
)	O
cell	O
cycle	O
analysis	O
c	O
)	O
protein	O
expression	O
of	O
proliferation	O
modulators	O
(	O
p27	B-GP
,	O
p21	B-GP
,	O
cyclin	B-GP
D1	I-GP
and	O
cyclin	B-GP
E	I-GP
).	O

Results	O

The	O
αMSH	B-GP
acted	O
as	O
a	O
mitogenic	O
agent	O
in	O
primary	O
cultures	O
of	O
human	B-OG
melanocytes	O
,	O
whereas	O
it	O
determined	O
a	O
slow	O
down	O
of	O
proliferation	O
in	O
melanoma	B-DS
cell	O
lines	O
.	O

FSK	O
,	O
as	O
an	O
inducer	O
of	O
the	O
cAMP	O
/	O
PKA	B-GP
pathway	O
,	O
reproduced	O
the	O
αMSH	B-GP
mediated	O
effect	O
on	O
proliferation	O
in	O
NHMs	O
but	O
it	O
did	O
not	O
mimic	O
the	O
αMSH	B-GP
effect	O
on	O
proliferation	O
in	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
melanoma	B-DS
cell	O
lines	O
.	O

Meanwhile	O
,	O
3	O
M3	O
-	O
FBS	O
(	O
3	O
M3	O
),	O
as	O
an	O
inducer	O
of	O
PI	O
(	O
4	O
,	O
5	O
)	O
P2	O
/	O
PLC	B-GP
pathway	O
,	O
reproduced	O
the	O
αMSH	B-GP
proliferative	O
effect	O
.	O

Further	O
experiments	O
,	O
treating	O
melanoma	B-DS
cell	O
lines	O
with	O
αMSH	B-GP
in	O
the	O
presence	O
/	O
absence	O
of	O
GW9662	O
,	O
as	O
an	O
inhibitor	O
of	O
PPARγ	B-GP
,	O
confirmed	O
the	O
key	O
role	O
of	O
this	O
transcription	B-GP
factor	I-GP
in	O
decreasing	O
cell	O
proliferation	O
in	O
response	O
to	O
the	O
hormone	O
exposure	O
.	O

Conclusions	O

In	O
both	O
melanoma	B-DS
cell	O
lines	O
,	O
αMSH	B-GP
determined	O
the	O
reduction	O
of	O
proliferation	O
through	O
the	O
PI	O
(	O
4	O
,	O
5	O
)	O
P2	O
/	O
PLC	B-GP
pathway	O
,	O
employing	O
PPARγ	B-GP
as	O
an	O
effector	O
element	O
.	O

These	O
evidence	O
could	O
offer	O
perspectives	O
for	O
new	O
therapeutic	O
approaches	O
for	O
melanoma	B-DS
.	O

Electronic	O
supplementary	O
material	O

The	O
online	O
version	O
of	O
this	O
article	O
(	O
10	O
.	O
1186	O
/	O
s13046	O
-	O
017	O
-	O
0611	O
-	O
4	O
)	O
contains	O
supplementary	O
material	O
,	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O

Background	O

The	O
Melanocortin	B-GP
-	I-GP
1	I-GP
receptor	I-GP
(	O
MC1R	B-GP
),	O
expressed	O
on	O
the	O
surface	O
of	O
melanocytes	O
and	O
melanoma	B-DS
cells	O
,	O
and	O
its	O
ligand	O
,	O
the	O
α	B-GP
-	I-GP
Melanocyte	I-GP
Stimulating	I-GP
Hormone	I-GP
(	O
αMSH	B-GP
),	O
represent	O
a	O
key	O
interaction	O
in	O
the	O
control	O
of	O
melanogenesis	O
[	O
1	O
–	O
4	O
].	O

MC1R	B-GP
activation	O
stimulates	O
cAMP	O
synthesis	O
via	O
G	B-GP
-	I-GP
protein	I-GP
,	O
which	O
in	O
turn	O
mediates	O
the	O
phosphorylation	O
of	O
the	O
cAMP	B-GP
responsive	I-GP
element	I-GP
-	I-GP
binding	I-GP
protein	I-GP
(	O
CREB	B-GP
)	O
transcription	B-GP
factor	I-GP
.	O

In	O
turn	O
,	O
CREB	B-GP
participates	O
in	O
the	O
activation	O
of	O
Micropthalmia	B-GP
Transcription	I-GP
Factor	I-GP
(	O
MITF	B-GP
),	O
the	O
crucial	O
transcription	B-GP
factor	I-GP
for	O
melanocyte	O
differentiation	O
and	O
melanogenesis	O
[	O
5	O
,	O
6	O
].	O

We	O
previously	O
identified	O
a	O
new	O
pathway	O
between	O
αMSH	B-GP
and	O
Peroxisome	B-GP
Proliferator	I-GP
Activated	I-GP
Receptor	I-GP
(	O
PPARγ	B-GP
)	O
on	O
B16	O
-	O
F10	O
mouse	B-OG
melanoma	B-DS
cell	O
line	O
[	O
7	O
].	O

In	O
the	O
same	O
work	O
we	O
demonstrated	O
that	O
αMSH	B-GP
induced	O
the	O
translocation	O
of	O
PPARγ	B-GP
into	O
the	O
nucleus	O
.	O

This	O
effect	O
was	O
not	O
reproduced	O
by	O
Forskolin	O
(	O
FSK	O
)	O
(	O
a	O
direct	O
activator	O
of	O
the	O
cAMP	O
/	O
PKA	B-GP
pathway	O
by	O
[	O
8	O
])	O
and	O
was	O
dependent	O
on	O
the	O
activation	O
of	O
the	O
PI	O
(	O
4	O
,	O
5	O
)	O
P2	O
/	O
PLC	B-GP
pathway	O
.	O

Moreover	O
,	O
a	O
preliminary	O
experiment	O
showed	O
that	O
the	O
B10	O
-	O
F10	O
cell	O
line	O
responded	O
to	O
αMSH	B-GP
by	O
reducing	O
proliferation	O
and	O
that	O
PPARγ	B-GP
was	O
directly	O
involved	O
in	O
this	O
effect	O
.	O

PPARγ	B-GP
is	O
a	O
transcription	B-GP
factor	I-GP
capable	O
of	O
promoting	O
pleyotropic	O
effects	O
,	O
including	O
the	O
control	O
of	O
proliferation	O
[	O
9	O
,	O
10	O
].	O

In	O
fact	O
,	O
many	O
studies	O
in	O
cancer	B-DS
therapy	O
employ	O
pharmacological	O
agonists	O
of	O
PPARγ	B-GP
with	O
the	O
aim	O
of	O
promoting	O
a	O
slow	O
down	O
of	O
the	O
cell	O
cycle	O
[	O
11	O
,	O
12	O
].	O

Only	O
sporadic	O
and	O
very	O
old	O
studies	O
have	O
dealt	O
with	O
the	O
capacity	O
of	O
activated	O
MC1R	B-GP
to	O
modulate	O
proliferation	O
in	O
melanoma	B-DS
cells	O
and	O
melanocytes	O
:	O
transformed	O
cells	O
respond	O
to	O
αMSH	B-GP
by	O
proliferating	O
or	O
down	O
-	O
regulating	O
proliferation	O
,	O
according	O
to	O
the	O
degree	O
of	O
pigmentation	O
and	O
the	O
progression	O
of	O
the	O
pathology	O
[	O
13	O
,	O
14	O
];	O
primary	O
cultures	O
of	O
human	B-OG
melanocytes	O
respond	O
to	O
αMSH	B-GP
with	O
a	O
hyper	O
-	O
proliferative	O
behaviour	O
[	O
1	O
,	O
3	O
,	O
15	O
–	O
17	O
]	O
and	O
some	O
authors	O
have	O
defined	O
αMSH	B-GP
as	O
a	O
mitogenic	O
agent	O
for	O
melanocytes	O
[	O
1	O
,	O
3	O
].	O

The	O
mechanism	O
promoting	O
hyper	O
-	O
proliferation	O
in	O
melanocytes	O
could	O
be	O
recognized	O
in	O
the	O
cAMP	O
/	O
PKA	B-GP
pathway	O
itself	O
(	O
the	O
canonical	O
pathway	O
triggered	O
by	O
the	O
activation	O
of	O
MC1R	B-GP
).	O

In	O
fact	O
,	O
cAMP	O
elevating	O
agents	O
,	O
such	O
as	O
FSK	O
,	O
enhance	O
the	O
proliferation	O
and	O
melanogenesis	O
of	O
cultured	O
human	B-OG
melanocytes	O
[	O
18	O
–	O
20	O
].	O

Here	O
we	O
worked	O
on	O
B16	O
-	O
F10	O
murine	O
melanoma	B-DS
,	O
on	O
Mel	O
13	O
human	B-OG
melanoma	B-DS
cell	O
line	O
and	O
on	O
primary	O
human	B-OG
melanocytes	O
NHM	O
1	O
and	O
NHM	O
2	O
.	O

All	O
human	B-OG
cell	O
lines	O
were	O
set	O
up	O
in	O
our	O
laboratory	O
starting	O
from	O
biopsy	O
explants	O
.	O

All	O
cell	O
lines	O
expressed	O
a	O
wild	O
type	O
MC1R	B-GP
and	O
responded	O
to	O
αMSH	B-GP
in	O
terms	O
of	O
pigmentation	O
(	O
see	O
Methods	O
).	O

We	O
aimed	O
to	O
confirm	O
the	O
different	O
proliferative	O
effects	O
,	O
in	O
response	O
to	O
αMSH	B-GP
,	O
in	O
melanoma	B-DS
and	O
in	O
healthy	O
condition	O
.	O

Moreover	O
we	O
proposed	O
to	O
verify	O
whether	O
the	O
cAMP	O
/	O
PKA	B-GP
pathway	O
and	O
the	O
PLC	B-GP
/	O
PPARγ	B-GP
pathway	O
could	O
exert	O
an	O
antagonistic	O
function	O
in	O
the	O
control	O
of	O
proliferation	O
.	O

Furthermore	O
,	O
we	O
aimed	O
to	O
deepen	O
the	O
knowledge	O
of	O
the	O
mechanism	O
responsible	O
for	O
the	O
down	O
-	O
proliferative	O
response	O
of	O
melanoma	B-DS
cells	O
after	O
exposure	O
to	O
αMSH	B-GP
,	O
by	O
analyzing	O
cell	O
proliferation	O
and	O
protein	O
levels	O
of	O
p27	B-GP
,	O
p21	B-GP
,	O
cyclin	B-GP
D1	I-GP
and	O
E	O
,	O
as	O
typical	O
proliferation	O
modulators	O
.	O

Cyclin	B-GP
D1	I-GP
and	O
E	O
and	O
their	O
associated	O
cyclin	B-GP
-	I-GP
dependent	I-GP
kinases	I-GP
(	O
CDKs	B-GP
:	O
CDK4	B-GP
and	O
CDK6	B-GP
for	O
cyclin	B-GP
D1	I-GP
;	O
CDK2	B-GP
for	O
cyclin	B-GP
E	I-GP
)	O
are	O
central	O
mediators	O
in	O
transition	O
from	O
G1	O
and	O
S	O
phase	O
[	O
21	O
,	O
22	O
].	O

On	O
the	O
contrary	O
,	O
p21	B-GP
and	O
p27	B-GP
represents	O
two	O
G1	O
-	O
check	O
point	O
CDK	B-GP
inhibitors	O
[	O
23	O
–	O
25	O
].	O

Our	O
previous	O
study	O
mainly	O
underlined	O
the	O
existence	O
of	O
the	O
αMSH	B-GP
/	O
PPARγ	B-GP
pathway	O
in	O
association	O
with	O
the	O
canonical	O
cAMP	O
/	O
PKA	B-GP
,	O
but	O
only	O
started	O
to	O
deal	O
with	O
its	O
effects	O
on	O
proliferation	O
.	O

Moreover	O
,	O
it	O
essentially	O
employed	O
the	O
B16	O
-	O
F10	O
murine	O
melanoma	B-DS
cell	O
line	O
[	O
7	O
].	O

The	O
present	O
study	O
extended	O
the	O
analysis	O
of	O
the	O
αMSH	B-GP
/	O
PPARγ	B-GP
pathway	O
to	O
human	B-OG
cell	O
lines	O
.	O

The	O
novelty	O
of	O
this	O
work	O
was	O
to	O
focus	O
on	O
the	O
PLC	B-GP
/	O
PPARγ	B-GP
and	O
cAMP	O
/	O
PKA	B-GP
pathways	O
on	O
cell	O
proliferation	O
.	O

In	O
summary	O
,	O
on	O
cell	O
lines	O
expressing	O
a	O
wild	O
type	O
MC1R	B-GP
and	O
responding	O
to	O
αMSH	B-GP
in	O
terms	O
of	O
pigmentation	O
,	O
this	O
study	O
confirmed	O
the	O
hyper	O
-	O
proliferative	O
effect	O
of	O
αMSH	B-GP
in	O
primary	O
cultures	O
of	O
melanocytes	O
and	O
the	O
opposite	O
effect	O
in	O
melanoma	B-DS
cell	O
lines	O
.	O

Moreover	O
,	O
it	O
associated	O
an	O
antagonistic	O
function	O
to	O
the	O
cAMP	O
/	O
PKA	B-GP
and	O
the	O
PLC	B-GP
/	O
PPARγ	B-GP
pathways	O
in	O
the	O
control	O
of	O
proliferation	O
.	O

Finally	O
,	O
it	O
highlighted	O
that	O
the	O
reduction	O
of	O
proliferation	O
,	O
observed	O
in	O
melanoma	B-DS
cell	O
lines	O
exposed	O
to	O
αMSH	B-GP
,	O
showed	O
characteristics	O
of	O
cell	O
cycle	O
withdrawal	O
.	O

A	O
more	O
in	O
-	O
depth	O
analysis	O
of	O
these	O
mechanisms	O
could	O
provide	O
useful	O
information	O
for	O
the	O
development	O
of	O
innovative	O
therapeutic	O
strategies	O
for	O
melanoma	B-DS
.	O

Methods	O

Cell	O
lines	O
and	O
treatments	O

B16	O
-	O
F10	O
cell	O
line	O
is	O
a	O
classical	O
melanoma	B-DS
cell	O
line	O
widely	O
employed	O
in	O
pigmentation	O
studies	O
,	O
because	O
it	O
expresses	O
a	O
wild	O
type	O
MC1R	B-GP
,	O
with	O
an	O
intact	O
transduction	O
machinery	O
,	O
which	O
is	O
activated	O
in	O
response	O
to	O
receptor	O
stimulation	O
[	O
26	O
].	O

B16	O
-	O
F10	O
mouse	B-OG
melanoma	B-DS
cells	O
were	O
cultured	O
in	O
Dulbecco	O
’	O
s	O
modified	O
Eagle	O
’	O
s	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
heat	O
-	O
inactivated	O
7	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
and	O
antibiotics	O
(	O
all	O
products	O
purchased	O
by	O
EuroClone	O
,	O
Milan	O
,	O
Italy	O
).	O

The	O
human	B-OG
Mel13	O
-	O
SM	O
melanoma	B-DS
cell	O
line	O
(	O
Mel	O
13	O
)	O
was	O
isolated	O
in	O
our	O
laboratory	O
as	O
previously	O
reported	O
[	O
27	O
],	O
exclusively	O
from	O
excess	O
parts	O
of	O
the	O
biopsy	O
collected	O
for	O
histological	O
examination	O
,	O
without	O
compromising	O
the	O
standard	O
diagnostic	O
procedure	O
.	O

Mel	O
13	O
derived	O
from	O
a	O
skin	O
metastasis	O
removed	O
from	O
the	O
leg	O
of	O
a	O
52	O
-	O
year	O
-	O
old	O
male	O
(	O
pT3bN0M1	O
,	O
stage	O
IV	O
).	O

Mel	O
13	O
cell	O
line	O
was	O
grown	O
in	O
OptiMEM	O
(	O
Invitrogen	O
Life	O
Technologies	O
Italia	O
,	O
Monza	O
,	O
Italy	O
)	O
medium	O
containing	O
10	O
%	O
FBS	O
and	O
antibiotics	O
.	O

All	O
the	O
experiments	O
were	O
performed	O
at	O
low	O
cell	O
culture	O
passage	O
.	O

Two	O
primary	O
human	B-OG
melanocyte	O
cultures	O
,	O
NHM	O
1	O
and	O
NHM	O
2	O
respectively	O
(	O
NHMs	O
),	O
were	O
set	O
up	O
in	O
our	O
laboratory	O
from	O
neonatal	O
foreskin	O
in	O
accordance	O
with	O
a	O
previously	O
described	O
procedure	O
[	O
28	O
].	O

NHMs	O
were	O
selectively	O
grown	O
in	O
the	O
defined	O
medium	O
M254	O
(	O
Invitrogen	O
Life	O
Technologies	O
Italia	O
,	O
Monza	O
,	O
Italy	O
)	O
and	O
Human	B-OG
melanocyte	O
growth	O
supplements	O
(	O
HMGS	O
)	O
(	O
Invitrogen	O
Life	O
Technologies	O
Italia	O
,	O
Monza	O
,	O
Italy	O
).	O

NHMs	O
were	O
sub	O
-	O
cultured	O
once	O
a	O
week	O
and	O
experiments	O
carried	O
out	O
on	O
cells	O
between	O
passages	O
2	O
to	O
6	O
.	O

B16	O
-	O
F10	O
cell	O
cultures	O
and	O
human	B-OG
melanoma	B-DS
cells	O
were	O
plated	O
and	O
24	O
h	O
later	O
were	O
stimulated	O
with	O
chemicals	O
in	O
fresh	O
medium	O
.	O

Primary	O
human	B-OG
melanocytes	O
were	O
plated	O
and	O
24	O
h	O
later	O
were	O
stimulated	O
with	O
chemicals	O
in	O
a	O
fresh	O
medium	O
deprived	O
of	O
bovine	O
pituitary	O
extract	O
(	O
BPE	O
)	O
and	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
).	O

The	O
following	O
doses	O
of	O
chemicals	O
were	O
employed	O
:	O
10	O
−	O
7	O
M	O
αMSH	B-GP
(	O
Sigma	O
-	O
Aldrich	O
Srl	O
,	O
Milan	O
,	O
Italy	O
);	O
3	O
μM	O
GW9662	O
(	O
Sigma	O
-	O
Aldrich	O
Srl	O
,	O
Milan	O
,	O
Italy	O
)	O
a	O
potent	O
and	O
irreversible	O
antagonist	O
of	O
PPARγ	B-GP
[	O
29	O
];	O
15	O
μM	O
3	O
M3	O
-	O
FBS	O
(	O
3	O
M3	O
)	O
(	O
Merck	O
KGaA	O
,	O
Darmstadt	O
,	O
Germany	O
),	O
a	O
PLC	B-GP
inducer	O
[	O
30	O
];	O
1	O
μM	O
Forskolin	O
(	O
FSK	O
)	O
(	O
Sigma	O
-	O
Sigma	O
-	O
Aldrich	O
Srl	O
,	O
Milan	O
,	O
Italy	O
),	O
a	O
cAMP	O
-	O
stimulating	O
agent	O
[	O
8	O
].	O

Ethical	O
statement	O

Institute	O
Research	O
Ethics	O
Committee	O
(	O
IFO	O
)	O
approval	O
was	O
obtained	O
to	O
collect	O
samples	O
of	O
human	B-OG
material	O
for	O
research	O
.	O

The	O
Declaration	O
of	O
Helsinki	O
Principles	O
was	O
followed	O
,	O
and	O
patients	O
gave	O
written	O
informed	O
consent	O
.	O

For	O
biopsies	O
obtained	O
from	O
minors	O
written	O
consent	O
was	O
given	O
by	O
the	O
parents	O
or	O
legal	O
guardians	O
.	O

RNA	O
extraction	O
and	O
quantitative	O
real	O
-	O
time	O
RT	O
-	O
PCR	O

Total	O
RNA	O
was	O
isolated	O
using	O
the	O
Aurum	O
™	O
Total	O
RNA	O
Mini	O
kit	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
Srl	O
,	O
Milan	O
,	O
Italy	O
).	O

Following	O
DNAse	B-GP
I	I-GP
treatment	O
,	O
cDNA	O
was	O
synthesized	O
using	O
oligo	O
-	O
dT	O
primers	O
and	O
using	O
ImProm	O
-	O
II	O
™	O
Reverse	B-GP
Transcriptase	I-GP
(	O
Promega	O
Corporation	O
,	O
Madison	O
,	O
WI	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

Quantitative	O
real	O
time	O
RT	O
-	O
PCR	O
was	O
performed	O
in	O
a	O
total	O
volume	O
of	O
15	O
μl	O
with	O
SYBR	O
Green	O
PCR	O
Master	O
Mix	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
Srl	O
)	O
and	O
200	O
nM	O
concentration	O
of	O
each	O
primer	O
.	O

The	O
primer	O
sequences	O
were	O
as	O
follows	O
:	O
hMC1R	B-GP
sense	O
:	O
5	O
′-	O
CCTGAAGACCTCACTAGG	O
-	O
3	O
′	O
and	O
antisense	O
:	O
5	O
′-	O
CATCTTGTAGAGCCTGAG	O
-	O
3	O
′;	O
mMC1R	B-GP
sense	O
:	O
5	O
′-	O
CAAGGAGGTGCTGCTGTG	O
-	O
3	O
and	O
antisense	O
:	O
5	O
′-	O
TAGACAAATGGAGATCAGGAAGG	O
-	O
3	O
′,	O
β	B-GP
-	I-GP
actin	I-GP
sense	O
:	O
5	O
′-	O
GACAGGATGCAGAAGGAGATTACT	O
-	O
3	O
′	O
and	O
antisense	O
5	O
′-	O
TGATCCACATCTGCTGGAAGGT	O
-	O
3	O
′.	O

Reactions	O
were	O
carried	O
out	O
in	O
triplicate	O
using	O
the	O
Real	O
-	O
Time	O
Detection	O
System	O
iQ5	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
Srl	O
)	O
supplied	O
with	O
iCycler	O
IQ5	O
optical	O
system	O
software	O
version	O
2	O
.	O
0	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
Srl	O
).	O

Melt	O
curve	O
analysis	O
was	O
performed	O
to	O
confirm	O
the	O
specificity	O
of	O
the	O
amplified	O
products	O
.	O
β	B-GP
-	I-GP
actin	I-GP
was	O
used	O
as	O
an	O
endogenous	O
control	O
.	O

Immunofluorescence	O
analysis	O

Cells	O
grown	O
on	O
coverslips	O
previously	O
coated	O
with	O
2	O
%	O
gelatin	O
on	O
24	O
-	O
well	O
plates	O
were	O
treated	O
with	O
3	O
M3	O
(	O
15	O
μM	O
)	O
for	O
1	O
,	O
3	O
and	O
6	O
h	O
.	O

For	O
immunolabelling	O
with	O
anti	O
-	O
PPARγ	B-GP
rabbit	B-OG
antibody	O
(	O
1	O
:	O
50	O
in	O
PBS	O
)	O
(	O
Cell	O
Signalling	O
Tecnology	O
,	O
New	O
England	O
Biolabs	O
,	O
UK	O
)	O
cells	O
were	O
fixed	O
in	O
methanol	O
for	O
4	O
min	O
.	O
at	O
−	O
20	O
°	O
C	O
.	O

The	O
primary	O
antibody	O
was	O
visualized	O
by	O
using	O
anti	O
-	O
rabbit	B-OG
IgG	B-GP
-	O
Alexa	O
Fluor	O
555	O
conjugated	O
antibody	O
(	O
1	O
:	O
800	O
in	O
PBS	O
)	O
(	O
Cell	O
Signaling	O
,	O
Tecnology	O
,	O
New	O
England	O
Biolabs	O
,	O
UK	O
).	O

Nuclei	O
were	O
visualized	O
with	O
DAPI	O
(	O
Sigma	O
-	O
Aldrich	O
Srl	O
).	O

Fluorescence	O
signals	O
were	O
analyzed	O
by	O
scanning	O
cells	O
in	O
a	O
series	O
of	O
sequential	O
sections	O
with	O
an	O
ApoTome	O
System	O
(	O
Zeiss	O
,	O
Oberkochen	O
,	O
Germany	O
);	O
image	O
analysis	O
was	O
performed	O
by	O
the	O
Axiovision	O
software	O
(	O
Zeiss	O
)	O
and	O
3D	O
reconstruction	O
of	O
a	O
selection	O
of	O
three	O
central	O
optical	O
sections	O
was	O
shown	O
in	O
each	O
image	O
.	O

Quantitative	O
analysis	O
of	O
the	O
extent	O
of	O
PPARγ	B-GP
/	O
DAPI	O
colocalization	O
was	O
determined	O
using	O
Axiovision	O
colocalization	O
module	O
(	O
Zeiss	O
)	O
analyzing	O
100	O
cells	O
for	O
each	O
condition	O
randomly	O
taken	O
from	O
10	O
different	O
microscopic	O
fields	O
.	O

Results	O
are	O
expressed	O
as	O
fold	O
increase	O
of	O
colocalization	O
signals	O
with	O
respect	O
to	O
the	O
values	O
obtained	O
in	O
untreated	O
cells	O
and	O
are	O
reported	O
as	O
mean	O
values	O
±	O
SD	O
(%).	O

Three	O
distinct	O
experiments	O
were	O
analyzed	O
.	O

For	O
immunolabelling	O
with	O
anti	O
-	O
MC1R	B-GP
(	O
N	O
-	O
19	O
)	O
goat	B-OG
antibody	O
(	O
1	O
:	O
50	O
in	O
PBS	O
)	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
INC	O
)	O
cells	O
were	O
fixed	O
in	O
PFA	O
4	O
%	O
for	O
15	O
min	O
at	O
room	O
temperature	O
.	O

The	O
primary	O
antibody	O
was	O
visualized	O
using	O
anti	O
-	O
goat	B-OG
IgG	B-GP
-	O
Alexa	O
Fluor	O
488	O
conjugated	O
antibody	O
(	O
1	O
:	O
800	O
in	O
PBS	O
)	O
(	O
ThermoFisher	O
Scientific	O
).	O

Nuclei	O
were	O
visualized	O
with	O
DAPI	O
(	O
Sigma	O
-	O
Aldrich	O
Srl	O
).	O

Western	O
blot	O
analysis	O

Cells	O
were	O
lysed	O
in	O
denaturing	O
conditions	O
supplemented	O
with	O
a	O
protease	B-GP
inhibitor	O
cocktail	O
(	O
Roche	O
,	O
Mannheim	O
,	O
Germany	O
).	O

The	O
protein	O
concentration	O
of	O
extracts	O
was	O
estimated	O
with	O
Bradford	O
reagent	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
Srl	O
,	O
Milan	O
,	O
Italy	O
).	O

Equal	O
amounts	O
of	O
proteins	O
were	O
then	O
separated	O
on	O
acrylammide	O
SDS	O
-	O
PAGE	O
,	O
transferred	O
onto	O
nitrocellulose	O
(	O
Amersham	O
Biosciences	O
,	O
Milan	O
,	O
Italy	O
)	O
and	O
then	O
treated	O
overnight	O
at	O
4	O
°	O
C	O
with	O
:	O
anti	O
-	O
tyrosinase	B-GP
antibody	O
,	O
anti	O
-	O
cyclin	B-GP
E	I-GP
antibody	O
(	O
1	O
:	O
1000	O
;	O
Santa	O
Cruz	O
Biotechnology	O
Inc	O
.,	O
Santa	O
Cruz	O
,	O
CA	O
,	O
USA	O
);	O
anti	O
-	O
p27	B-GP
antibody	O
,	O
anti	O
-	O
p21	B-GP
antibody	O
,	O
anti	O
-	O
cyclin	B-GP
D1	I-GP
antibody	O
(	O
all	O
1	O
:	O
1000	O
;	O
Cell	O
Signalling	O
Technology	O
,	O
New	O
England	O
Biolabs	O
,	O
UK	O
).	O

HRP	O
-	O
conjugated	O
goat	B-OG
anti	O
-	O
mouse	B-OG
(	O
1	O
:	O
3000	O
;	O
Cell	O
Signalling	O
Technology	O
)	O
or	O
anti	O
-	O
rabbit	B-OG
IgG	B-GP
(	O
1	O
:	O
8000	O
;	O
Cell	O
Signalling	O
Technology	O
)	O
were	O
used	O
as	O
secondary	O
antibodies	O
.	O

Antibody	O
complexes	O
were	O
visualized	O
using	O
the	O
an	O
enhanced	O
chemiluminescence	O
reagent	O
(	O
ECL	O
)	O
(	O
Amersham	O
Biosciences	O
,	O
Milan	O
,	O
Italy	O
).	O

A	O
subsequent	O
hybridization	O
with	O
anti	O
-	O
GAPDH	B-GP
or	O
anti	O
-	O
HSP70	B-GP
(	O
both	O
1	O
:	O
5000	O
;	O
Santa	O
Cruz	O
Biotechnology	O
Inc	O
.,	O
Santa	O
Cruz	O
,	O
CA	O
,	O
USA	O
)	O
was	O
used	O
to	O
estimate	O
the	O
equal	O
protein	O
loading	O
.	O

Densitometric	O
analysis	O
was	O
performed	O
using	O
a	O
GS	O
-	O
800	O
Calibrated	O
Image	O
Densitometer	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
Srl	O
,	O
Milan	O
,	O
Italy	O
)	O
or	O
with	O
UVITEC	O
Imaging	O
System	O
(	O
Cambridge	O
,	O
UK	O
).	O

Results	O
refer	O
to	O
three	O
independent	O
experiments	O
.	O

Cell	O
number	O
analysis	O

Cells	O
were	O
plated	O
in	O
a	O
12	O
well	O
plate	O
at	O
a	O
density	O
of	O
1	O
X	O
104	O
cells	O
/	O
well	O
and	O
were	O
grown	O
overnight	O
.	O

Cells	O
were	O
treated	O
with	O
10	O
−	O
7	O
M	O
αMSH	B-GP
,	O
3	O
μM	O
GW9662	O
,	O
15	O
μM	O
3	O
M3	O
and	O
1	O
μM	O
FSK	O
at	O
different	O
time	O
points	O
,	O
in	O
accordance	O
with	O
the	O
experimental	O
design	O
.	O

Cell	O
number	O
was	O
determined	O
by	O
cell	O
counting	O
using	O
a	O
phase	O
contrast	O
microscope	O
.	O

None	O
of	O
the	O
employed	O
doses	O
of	O
chemicals	O
determined	O
positivity	O
to	O
the	O
Trypan	O
blue	O
exclusion	O
assay	O
test	O
.	O

The	O
results	O
presented	O
are	O
the	O
average	O
of	O
three	O
experiments	O
in	O
triplicate	O
.	O

Flow	O
cytometric	O
analysis	O
of	O
cell	O
cycle	O

Cells	O
were	O
harvested	O
by	O
treatment	O
with	O
0	O
.	O
25	O
%	O
trypsin	B-GP
,	O
fixed	O
with	O
ice	O
-	O
cold	O
70	O
%	O
ethanol	O
solution	O
,	O
and	O
stained	O
in	O
PBS	O
containing	O
propidium	O
iodide	O
(	O
100	O
μg	O
/	O
ml	O
)	O
and	O
RNase	B-GP
A	I-GP
(	O
90	O
μg	O
/	O
ml	O
)	O
overnight	O
at	O
4	O
°	O
C	O
.	O

The	O
DNA	O
content	O
of	O
the	O
cells	O
was	O
measured	O
by	O
FACScalibur	O
flow	O
cytometer	O
(	O
Becton	O
Dickinson	O
,	O
Franklin	O
Lakes	O
,	O
NJ	O
,	O
USA	O
).	O

A	O
total	O
number	O
of	O
104	O
cells	O
for	O
each	O
sample	O
were	O
acquired	O
.	O

Flow	O
cytometric	O
histograms	O
were	O
analyzed	O
by	O
defining	O
borders	O
between	O
pre	O
-	O
G1	O
,	O
G1	O
,	O
S	O
and	O
G2	O
+	O
M	O
phase	O
populations	O
.	O

Cell	O
Quest	O
Software	O
was	O
used	O
to	O
analyze	O
data	O
.	O

Transfection	O
and	O
luciferase	B-GP
assay	O

Cells	O
were	O
transfected	O
with	O
pGL3	O
-(	O
Jwt	O
)	O
3TKLuc	O
reporter	O
construct	O
[	O
31	O
]	O
using	O
specific	O
Amaxa	O
®	O
Nucleofector	O
kits	O
(	O
Lonza	O
,	O
Basel	O
,	O
Switzerland	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

24	O
h	O
after	O
treatment	O
with	O
10	O
−	O
7	O
M	O
αMSH	B-GP
or	O
15	O
μM	O
3	O
M3	O
,	O
cells	O
were	O
harvested	O
in	O
100	O
μl	O
lysis	O
buffer	O
and	O
20	O
μl	O
of	O
the	O
extract	O
were	O
assayed	O
for	O
luciferase	B-GP
activity	O
using	O
Promega	O
’	O
s	O
Dual	O
Luciferase	B-GP
(	O
Promega	O
Corporation	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
protocol	O
.	O

The	O
renilla	O
luciferase	B-GP
plasmid	O
was	O
also	O
transfected	O
as	O
an	O
internal	O
control	O
for	O
monitoring	O
transfection	O
efficiency	O
and	O
for	O
normalizing	O
the	O
firefly	O
luciferase	B-GP
activity	O
.	O

The	O
luciferase	B-GP
activity	O
was	O
expressed	O
as	O
fold	O
of	O
the	O
activity	O
obtained	O
in	O
cells	O
treated	O
with	O
the	O
different	O
molecules	O
divided	O
by	O
luciferase	B-GP
activity	O
from	O
non	O
-	O
stimulated	O
cells	O
.	O

The	O
pGL3	O
-(	O
Jwt	O
)	O
3TKLuc	O
reporter	O
construct	O
is	O
described	O
elsewhere	O
[	O
31	O
].	O

The	O
results	O
represent	O
the	O
average	O
of	O
three	O
independent	O
experiments	O
performed	O
in	O
triplicate	O
.	O

Statistical	O
analyses	O

Data	O
are	O
presented	O
as	O
means	O
±	O
SD	O
.	O

The	O
Student	O
’	O
s	O
t	O
-	O
test	O
was	O
used	O
to	O
analyze	O
differences	O
.	O

Values	O
of	O
p	O
<	O
0	O
.	O
05	O
were	O
considered	O
significant	O
.	O

Results	O

αMSH	B-GP
reduced	O
melanoma	B-DS
cell	O
proliferation	O
while	O
it	O
exerted	O
a	O
mitogenic	O
effect	O
in	O
primary	O
human	B-OG
melanocytes	O

We	O
investigated	O
the	O
capacity	O
of	O
αMSH	B-GP
to	O
modulate	O
proliferation	O
in	O
primary	O
human	B-OG
melanocytes	O
NHM	O
1	O
and	O
NHM	O
2	O
,	O
in	O
B16	O
-	O
F10	O
murine	O
melanoma	B-DS
cell	O
line	O
and	O
in	O
the	O
Mel	O
13	O
human	B-OG
melanoma	B-DS
cell	O
line	O
.	O

All	O
these	O
cell	O
lines	O
were	O
characterized	O
by	O
the	O
genetic	O
nature	O
of	O
MC1R	B-GP
,	O
expressing	O
a	O
wild	O
type	O
MC1R	B-GP
and	O
responding	O
to	O
αMSH	B-GP
in	O
terms	O
of	O
pigmentation	O
(	O
see	O
Additional	O
file	O
1	O
and	O
Additional	O
file	O
2	O
:	O
Figure	O
S1	O
).	O

The	O
duplication	O
time	O
of	O
primary	O
cultures	O
of	O
human	B-OG
melanocytes	O
is	O
significantly	O
longer	O
with	O
respect	O
to	O
that	O
of	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
melanoma	B-DS
cell	O
line	O
(	O
30	O
/	O
40	O
h	O
vs	O
18	O
/	O
24	O
h	O
).	O

Thus	O
,	O
we	O
planned	O
to	O
perform	O
evaluations	O
at	O
suitable	O
times	O
to	O
highlight	O
variations	O
in	O
treated	O
samples	O
in	O
comparison	O
with	O
untreated	O
ones	O
.	O

The	O
exposure	O
to	O
10	O
−	O
7	O
M	O
αMSH	B-GP
for	O
3	O
and	O
6	O
days	O
,	O
significantly	O
increased	O
the	O
cell	O
number	O
in	O
both	O
NHMs	O
(	O
Fig	O
.	O
1a	O
).	O

Accordingly	O
,	O
48	O
h	O
hrs	O
of	O
treatment	O
with	O
the	O
hormone	O
significantly	O
decreased	O
the	O
proportion	O
of	O
cells	O
distributed	O
in	O
the	O
G0	O
/	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
(	O
Fig	O
.	O
1b	O
).	O

Instead	O
,	O
αMSH	B-GP
was	O
unable	O
to	O
act	O
as	O
a	O
mitogenic	O
agent	O
either	O
in	O
B16	O
-	O
F10	O
or	O
Mel	O
13	O
cell	O
lines	O
,	O
and	O
it	O
even	O
reduced	O
the	O
cell	O
number	O
.	O

This	O
effect	O
was	O
already	O
significant	O
after	O
24	O
h	O
of	O
treatment	O
(	O
Fig	O
.	O
1c	O
).	O

In	O
compliance	O
with	O
these	O
results	O
,	O
24	O
h	O
of	O
treatment	O
with	O
αMSH	B-GP
determined	O
a	O
significant	O
increase	O
in	O
the	O
proportion	O
of	O
cells	O
which	O
were	O
distributed	O
in	O
the	O
G0	O
/	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
(	O
Fig	O
.	O
1d	O
).	O

In	O
order	O
to	O
corroborate	O
the	O
αMSH	B-GP
effect	O
on	O
proliferation	O
slow	O
down	O
,	O
we	O
evaluated	O
the	O
expression	O
levels	O
of	O
G1	O
phase	O
related	O
proteins	O
(	O
p27	B-GP
,	O
p21	B-GP
,	O
cyclin	B-GP
D1	I-GP
and	O
E	O
),	O
in	O
response	O
to	O
the	O
hormone	O
exposure	O
.	O

In	O
preliminary	O
experiments	O
,	O
expression	O
levels	O
of	O
p27	B-GP
,	O
p21	B-GP
,	O
cyclin	B-GP
D1	I-GP
and	O
E	O
,	O
after	O
exposure	O
to	O
αMSH	B-GP
,	O
or	O
alternative	O
stimuli	O
(	O
see	O
below	O
),	O
were	O
followed	O
at	O
4	O
,	O
6	O
,	O
12	O
,	O
24	O
,	O
36	O
and	O
48	O
h	O
(	O
data	O
not	O
shown	O
).	O

Here	O
,	O
and	O
in	O
the	O
subsequent	O
experiments	O
(	O
also	O
see	O
following	O
paragraphs	O
),	O
we	O
reported	O
data	O
associated	O
with	O
times	O
of	O
maximal	O
proteins	O
modulation	O
.	O

In	O
both	O
melanoma	B-DS
cell	O
lines	O
,	O
the	O
expression	O
level	O
of	O
the	O
cyclin	B-GP
-	I-GP
dependent	I-GP
kinase	I-GP
inhibitor	I-GP
p27	I-GP
already	O
resulted	O
significantly	O
up	O
-	O
regulated	O
after	O
4	O
h	O
of	O
treatment	O
with	O
αMSH	B-GP
.	O

The	O
same	O
treatment	O
determined	O
a	O
significant	O
induction	O
of	O
the	O
expression	O
level	O
of	O
the	O
cyclin	B-GP
-	I-GP
dependent	I-GP
kinase	I-GP
inhibitor	I-GP
p21	I-GP
after	O
48	O
h	O
.	O

Consistently	O
,	O
αMSH	B-GP
exposure	O
significantly	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
both	O
cyclin	B-GP
D1	I-GP
and	O
E	O
after	O
6	O
h	O
(	O
Fig	O
.	O
1e	O
).	O

Thus	O
,	O
these	O
results	O
indicate	O
that	O
αMSH	B-GP
exerted	O
a	O
mitogenic	O
effect	O
in	O
primary	O
human	B-OG
melanocytes	O
while	O
it	O
reduced	O
melanoma	B-DS
cell	O
proliferation	O
.	O
Fig	O
.	O
1αMSH	O
acts	O
as	O
a	O
mitogenic	O
agent	O
in	O
NHMs	O
,	O
whereas	O
it	O
determined	O
a	O
slow	O
down	O
of	O
proliferation	O
in	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
melanoma	B-DS
cell	O
lines	O
.	O
a	O
Analysis	O
of	O
cell	O
number	O
performed	O
on	O
NHM	O
1	O
and	O
NHM	O
2	O
,	O
after	O
treatment	O
with	O
10	O
−	O
7	O
M	O
αMSH	B-GP
for	O
72	O
h	O
and	O
6	O
days	O
.	O

Cell	O
number	O
was	O
expressed	O
as	O
a	O
percent	O
variation	O
in	O
comparison	O
to	O
the	O
value	O
of	O
untreated	O
control	O
cells	O
.	O

Data	O
are	O
mean	O
values	O
±	O
SD	O
of	O
three	O
independent	O
experiments	O
performed	O
in	O
triplicate	O
.	O
*	O
p	O
<	O
0	O
.	O
01	O
(	O
vs	O
untreated	O
cells	O
).	O
b	O
Cell	O
-	O
cycle	O
distribution	O
was	O
evaluated	O
by	O
flow	O
cytometric	O
analysis	O
on	O
NHM	O
1	O
and	O
NHM	O
2	O
,	O
after	O
treatment	O
for	O
48	O
h	O
with	O
10	O
−	O
7	O
M	O
αMSH	B-GP
.	O

The	O
bar	O
graph	O
shows	O
the	O
distribution	O
of	O
cells	O
among	O
the	O
different	O
phases	O
of	O
the	O
cell	O
cycle	O
.	O

Data	O
are	O
mean	O
values	O
±	O
SD	O
of	O
three	O
independent	O
experiments	O
performed	O
in	O
duplicate	O
.	O
*	O
p	O
<	O
0	O
.	O
01	O
(	O
vs	O
untreated	O
cells	O
).	O
c	O
Analysis	O
of	O
cell	O
number	O
performed	O
on	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
,	O
after	O
treatment	O
with	O
10	O
−	O
7	O
M	O
αMSH	B-GP
for	O
24	O
and	O
48	O
h	O
.	O

Cell	O
number	O
was	O
expressed	O
as	O
a	O
percent	O
variation	O
in	O
comparison	O
to	O
the	O
value	O
of	O
untreated	O
control	O
cells	O
.	O

Data	O
are	O
mean	O
values	O
±	O
SD	O
of	O
three	O
independent	O
experiments	O
performed	O
in	O
triplicate	O
.	O
*	O
p	O
<	O
0	O
.	O
01	O
and	O
**	O
p	O
<	O
0	O
.	O
001	O
(	O
vs	O
untreated	O
cells	O
).	O
d	O
Cell	O
-	O
cycle	O
distribution	O
evaluated	O
by	O
flow	O
cytometric	O
analysis	O
on	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
,	O
after	O
treatment	O
for	O
24	O
h	O
with	O
10	O
−	O
7	O
M	O
αMSH	B-GP
.	O

The	O
bar	O
graph	O
shows	O
the	O
distribution	O
of	O
cells	O
among	O
the	O
different	O
phases	O
of	O
the	O
cell	O
cycle	O
.	O

Data	O
are	O
mean	O
values	O
±	O
SD	O
of	O
three	O
independent	O
experiments	O
performed	O
in	O
duplicate	O
.	O
*	O
p	O
<	O
0	O
.	O
01	O
(	O
vs	O
untreated	O
cells	O
).	O
e	O
Western	O
blot	O
analysis	O
of	O
p27	B-GP
(	O
4	O
h	O
),	O
p21	B-GP
(	O
48	O
h	O
),	O
cyclin	B-GP
D1	I-GP
and	O
cyclin	B-GP
E	I-GP
(	O
6	O
h	O
)	O
protein	O
expression	O
on	O
cell	O
lysate	O
of	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
,	O
treated	O
with	O
10	O
−	O
7	O
M	O
αMSH	B-GP
.	O

GAPDH	B-GP
or	O
HSP70	B-GP
were	O
used	O
as	O
an	O
equal	O
loading	O
control	O
.	O

Results	O
refer	O
to	O
three	O
independent	O
experiments	O
.	O

Representative	O
blots	O
are	O
shown	O
.	O

Densitometric	O
scanning	O
of	O
band	O
intensities	O
was	O
performed	O
to	O
quantify	O
the	O
change	O
of	O
protein	O
expression	O
(	O
control	O
value	O
taken	O
as	O
one	O
fold	O
in	O
each	O
case	O
).	O
*	O
p	O
<	O
0	O
,	O
01	O
(	O
vs	O
untreated	O
cells	O
)	O

Analysis	O
of	O
cAMP	O
/	O
PKA	B-GP
pathway	O
in	O
the	O
control	O
of	O
NHMs	O
and	O
melanoma	B-DS
cell	O
line	O
proliferation	O

The	O
cAMP	O
/	O
PKA	B-GP
pathway	O
is	O
the	O
pathway	O
through	O
which	O
the	O
MC1R	B-GP
is	O
universally	O
known	O
to	O
promote	O
melanin	O
synthesis	O
[	O
2	O
,	O
5	O
].	O

FSK	O
,	O
as	O
a	O
cAMP	O
elevating	O
agent	O
,	O
mimics	O
the	O
effects	O
of	O
αMSH	B-GP
on	O
melanogenesis	O
[	O
8	O
].	O

Furthermore	O
,	O
FSK	O
is	O
employed	O
in	O
defined	O
cell	O
culture	O
media	O
to	O
promote	O
the	O
proliferation	O
of	O
melanocytes	O
[	O
18	O
–	O
20	O
].	O

Here	O
,	O
we	O
verified	O
whether	O
FSK	O
was	O
able	O
to	O
mimic	O
the	O
effects	O
induced	O
by	O
αMSH	B-GP
on	O
proliferation	O
in	O
NHMs	O
.	O

In	O
both	O
NHMs	O
,	O
the	O
treatment	O
for	O
3	O
and	O
6	O
days	O
with	O
1	O
μM	O
FSK	O
promoted	O
a	O
significant	O
increase	O
in	O
cell	O
number	O
,	O
similar	O
to	O
that	O
produced	O
by	O
αMSH	B-GP
in	O
the	O
same	O
experimental	O
conditions	O
(	O
Fig	O
.	O
2a	O
).	O

In	O
compliance	O
with	O
these	O
results	O
,	O
the	O
exposure	O
to	O
FSK	O
promoted	O
a	O
significant	O
decrease	O
in	O
the	O
proportion	O
of	O
cells	O
distributed	O
in	O
the	O
G0	O
/	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
(	O
Fig	O
.	O
2b	O
).	O

Thus	O
,	O
these	O
results	O
indicate	O
that	O
the	O
αMSH	B-GP
-	O
dependent	O
mechanism	O
was	O
able	O
to	O
promote	O
hyper	O
-	O
proliferation	O
in	O
NHMs	O
can	O
be	O
recognized	O
in	O
the	O
cAMP	O
/	O
PKA	B-GP
pathway	O
.	O
Fig	O
.	O
2The	O
direct	O
induction	O
of	O
the	O
cAMP	O
/	O
PKA	B-GP
pathway	O
by	O
Forskolin	O
mimics	O
the	O
αMSH	B-GP
mediated	O
effect	O
on	O
proliferation	O
in	O
NHMs	O
but	O
it	O
does	O
not	O
reproduce	O
the	O
αMSH	B-GP
mediated	O
effect	O
on	O
proliferation	O
in	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
melanoma	B-DS
cell	O
lines	O
.	O
a	O
Analysis	O
of	O
cell	O
number	O
performed	O
on	O
NHM	O
1	O
and	O
NHM	O
2	O
,	O
after	O
treatment	O
with	O
10	O
−	O
7	O
M	O
αMSH	B-GP
or	O
1	O
μM	O
FSK	O
for	O
72	O
h	O
and	O
6	O
days	O
.	O

Cell	O
number	O
was	O
expressed	O
as	O
a	O
percent	O
variation	O
in	O
comparison	O
to	O
the	O
value	O
of	O
untreated	O
control	O
cells	O
.	O

Data	O
are	O
mean	O
values	O
±	O
SD	O
of	O
three	O
independent	O
experiments	O
performed	O
in	O
triplicate	O
.	O
*	O
p	O
<	O
0	O
.	O
01	O
(	O
vs	O
untreated	O
cells	O
).	O
b	O
Cell	O
-	O
cycle	O
distribution	O
evaluated	O
by	O
flow	O
cytometric	O
analysis	O
on	O
NHM	O
1	O
and	O
NHM	O
2	O
,	O
after	O
treatment	O
for	O
48	O
h	O
with	O
10	O
−	O
7	O
M	O
αMSH	B-GP
or	O
1	O
μM	O
FSK	O
.	O

The	O
bar	O
graph	O
shows	O
the	O
distribution	O
of	O
cells	O
among	O
the	O
different	O
phases	O
of	O
the	O
cell	O
cycle	O
.	O

Data	O
are	O
mean	O
values	O
±	O
SD	O
of	O
three	O
independent	O
experiments	O
performed	O
in	O
duplicate	O
.	O
*	O
p	O
<	O
0	O
.	O
01	O
and	O
**	O
p	O
<	O
0	O
.	O
001	O
(	O
vs	O
untreated	O
cells	O
).	O
c	O
Analysis	O
of	O
cell	O
number	O
performed	O
on	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
,	O
after	O
treatment	O
with	O
10	O
−	O
7	O
M	O
αMSH	B-GP
or	O
1	O
μM	O
FSK	O
for	O
24	O
and	O
48	O
h	O
.	O

Cell	O
number	O
was	O
expressed	O
as	O
a	O
percent	O
variation	O
in	O
comparison	O
with	O
the	O
value	O
of	O
untreated	O
control	O
cells	O
.	O

Data	O
are	O
mean	O
values	O
±	O
SD	O
of	O
three	O
independent	O
experiments	O
performed	O
in	O
triplicate	O
.	O
*	O
p	O
<	O
0	O
.	O
01	O
and	O
**	O
p	O
<	O
0	O
.	O
001	O
(	O
vs	O
untreated	O
cells	O
).	O
d	O
Cell	O
-	O
cycle	O
distribution	O
evaluated	O
by	O
flow	O
cytometric	O
analysis	O
on	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
,	O
after	O
treatment	O
for	O
24	O
h	O
with	O
10	O
−	O
7	O
M	O
αMSH	B-GP
or	O
1	O
μM	O
FSK	O
.	O

The	O
bar	O
graph	O
shows	O
the	O
distribution	O
of	O
cells	O
among	O
the	O
different	O
phases	O
of	O
the	O
cell	O
cycle	O
.	O

Data	O
are	O
mean	O
values	O
±	O
SD	O
of	O
three	O
independent	O
experiments	O
performed	O
in	O
duplicate	O
.	O
*	O
p	O
<	O
0	O
.	O
01	O
(	O
vs	O
untreated	O
cells	O
).	O
e	O
Western	O
blot	O
analysis	O
of	O
Cyclin	B-GP
D1	I-GP
protein	O
expression	O
on	O
cell	O
lysate	O
of	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
,	O
treated	O
with	O
FSK	O
for	O
1	O
,	O
2	O
,	O
4	O
and	O
6	O
h	O
.	O

HSP70	B-GP
was	O
used	O
as	O
an	O
equal	O
loading	O
control	O
.	O

Results	O
refer	O
to	O
three	O
independent	O
experiments	O
.	O

Representative	O
blots	O
are	O
shown	O
.	O

Densitometric	O
scanning	O
of	O
band	O
intensities	O
was	O
performed	O
to	O
quantify	O
the	O
change	O
of	O
protein	O
expression	O
(	O
control	O
value	O
taken	O
as	O
one	O
fold	O
in	O
each	O
case	O
).	O
*	O
p	O
<	O
0	O
,	O
01	O
and	O
**	O
p	O
<	O
0	O
.	O
001	O
(	O
vs	O
untreated	O
cells	O
)	O

In	O
our	O
previous	O
study	O
on	O
B16	O
-	O
F10	O
,	O
in	O
a	O
preliminary	O
experiment	O
of	O
cell	O
counting	O
,	O
we	O
demonstrated	O
that	O
αMSH	B-GP
induce	O
a	O
slow	O
down	O
of	O
proliferation	O
.	O

This	O
effect	O
was	O
mediated	O
by	O
the	O
αMSH	B-GP
/	O
PPARγ	B-GP
pathway	O
,	O
a	O
pathway	O
independent	O
of	O
the	O
cAMP	O
/	O
PKA	B-GP
canonical	O
pathway	O
[	O
7	O
].	O

Here	O
,	O
we	O
proposed	O
to	O
exclude	O
the	O
involvement	O
of	O
the	O
cAMP	O
/	O
PKA	B-GP
pathway	O
in	O
mediating	O
the	O
proliferation	O
slow	O
down	O
induced	O
by	O
αMSH	B-GP
in	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
melanoma	B-DS
cell	O
lines	O
.	O

Both	O
in	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
,	O
the	O
treatment	O
for	O
24	O
an	O
48	O
h	O
with	O
1	O
μM	O
FSK	O
caused	O
an	O
increase	O
in	O
cell	O
number	O
,	O
producing	O
an	O
opposite	O
effect	O
in	O
comparison	O
to	O
that	O
promoted	O
by	O
αMSH	B-GP
(	O
Fig	O
.	O
2c	O
).	O

The	O
analysis	O
of	O
cell	O
cycle	O
phase	O
distribution	O
,	O
after	O
24	O
h	O
of	O
treatment	O
with	O
FSK	O
,	O
corroborated	O
these	O
results	O
(	O
Fig	O
.	O
2d	O
).	O

Moreover	O
,	O
a	O
Western	O
blot	O
analysis	O
of	O
cyclin	B-GP
D1	I-GP
showed	O
a	O
rapid	O
induction	O
of	O
this	O
key	O
regulator	O
of	O
cell	O
cycle	O
progression	O
(	O
Fig	O
.	O
2e	O
).	O

These	O
results	O
,	O
confirmed	O
our	O
initial	O
hypothesis	O
.	O

In	O
fact	O
,	O
they	O
excluded	O
the	O
involvement	O
of	O
the	O
cAMP	O
/	O
PKA	B-GP
pathway	O
in	O
mediating	O
the	O
αMSH	B-GP
-	O
mediated	O
slow	O
down	O
of	O
proliferation	O
in	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
melanoma	B-DS
cell	O
lines	O
.	O

The	O
direct	O
induction	O
of	O
the	O
PI	O
(	O
4	O
,	O
5	O
)	O
P2	O
/	O
PLC	B-GP
pathway	O
by	O
3	O
M3	O
mimics	O
the	O
αMSH	B-GP
mediated	O
effect	O
on	O
proliferation	O
in	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
melanoma	B-DS
cell	O
lines	O

In	O
an	O
attempt	O
to	O
find	O
an	O
alternative	O
pathway	O
which	O
could	O
justify	O
the	O
proliferation	O
slow	O
down	O
induced	O
by	O
αMSH	B-GP
in	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
melanoma	B-DS
cell	O
lines	O
,	O
our	O
attention	O
focused	O
on	O
the	O
PI	O
(	O
4	O
,	O
5	O
)	O
P2	O
/	O
PLC	B-GP
pathway	O
[	O
7	O
].	O

PPARγ	B-GP
is	O
a	O
tumour	B-GP
suppressor	I-GP
gene	I-GP
[	O
9	O
,	O
10	O
].	O

Here	O
we	O
show	O
that	O
the	O
treatment	O
with	O
αMSH	B-GP
promoted	O
a	O
significant	O
induction	O
of	O
PPARγ	B-GP
transcriptional	O
activity	O
after	O
24	O
h	O
of	O
exposure	O
,	O
in	O
B16	O
-	O
F10	O
,	O
Mel	O
13	O
and	O
NHMs	O
.	O

Moreover	O
,	O
this	O
effect	O
was	O
consistently	O
higher	O
in	O
melanoma	B-DS
cell	O
lines	O
compared	O
to	O
NHMs	O
(	O
Fig	O
.	O
3	O
).	O

The	O
αMSH	B-GP
/	O
PPARγ	B-GP
connection	O
is	O
mediated	O
by	O
the	O
PI	O
(	O
4	O
,	O
5	O
)	O
P2	O
/	O
PLC	B-GP
pathway	O
.	O

In	O
turn	O
,	O
this	O
pathway	O
can	O
be	O
directly	O
activated	O
by	O
3	O
M3	O
[	O
30	O
].	O

Thus	O
,	O
we	O
tried	O
to	O
understand	O
whether	O
the	O
treatment	O
with	O
3	O
M3	O
was	O
able	O
to	O
mimic	O
the	O
down	O
-	O
proliferation	O
induced	O
by	O
αMSH	B-GP
in	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
melanoma	B-DS
cells	O
.	O
Fig	O
.	O
3Analysis	O
of	O
PPARγ	B-GP
transcriptional	O
activity	O
in	O
response	O
to	O
αMSH	B-GP
exposure	O
in	O
B16	O
-	O
F10	O
,	O
Mel	O
13	O
and	O
NHMs	O
.	O

Cells	O
were	O
transfected	O
with	O
pGL3	O
-(	O
Jwt	O
)	O
3TKLuc	O
reporter	O
construct	O
.	O

After	O
24	O
h	O
of	O
transfection	O
,	O
cells	O
were	O
treated	O
with	O
10	O
−	O
7	O
M	O
αMSH	B-GP
.	O

The	O
measurement	O
of	O
luciferase	B-GP
activity	O
was	O
carried	O
out	O
30	O
min	O
,	O
1	O
,	O
3	O
and	O
6	O
h	O
after	O
treatment	O
.	O

The	O
variability	O
of	O
transfection	O
was	O
normalized	O
with	O
renilla	O
luciferase	B-GP
activity	O
.	O

The	O
results	O
were	O
expressed	O
as	O
fold	O
change	O
with	O
respect	O
to	O
untreated	O
cells	O
.	O

Data	O
are	O
mean	O
values	O
±	O
SD	O
of	O
three	O
independent	O
experiments	O
performed	O
in	O
triplicate	O
,	O
*	O
p	O
<	O
0	O
.	O
01	O
and	O
**	O
p	O
<	O
0	O
.	O
001	O
(	O
vs	O
untreated	O
cells	O
)	O

Preliminary	O
checks	O
:	O
first	O
,	O
we	O
verified	O
the	O
capacity	O
of	O
3	O
M3	O
to	O
promote	O
:	O
(	O
a	O
)	O
calcium	O
fluxes	O
(	O
Additional	O
file	O
3	O
:	O
Figure	O
S2	O
),	O
(	O
b	O
)	O
PPARγ	B-GP
translocation	O
into	O
the	O
nucleus	O
(	O
Fig	O
.	O
4a	O
–	O
c	O
)	O
and	O
(	O
c	O
)	O
PPARγ	B-GP
transcriptional	O
activity	O
by	O
luciferase	B-GP
assay	O
(	O
Fig	O
.	O
4d	O
).	O

(	O
a	O
)	O
Concerning	O
the	O
analysis	O
of	O
calcium	O
fluxes	O
,	O
the	O
cells	O
previously	O
loaded	O
with	O
fluo	O
-	O
3	O
-	O
AM	O
,	O
responded	O
to	O
3	O
M3	O
treatment	O
with	O
an	O
increased	O
intra	O
-	O
cytoplasmic	O
calcium	O
,	O
which	O
was	O
significant	O
at	O
all	O
time	O
points	O
evaluated	O
.	O

This	O
increase	O
consisted	O
in	O
an	O
initial	O
response	O
,	O
which	O
reached	O
a	O
peak	O
after	O
2	O
min	O
,	O
followed	O
by	O
a	O
subsequent	O
decline	O
to	O
plateau	O
value	O
after	O
10	O
min	O
(	O
Additional	O
file	O
3	O
:	O
Figure	O
S2	O
).	O

(	O
b	O
)	O
We	O
also	O
evaluated	O
the	O
PPARγ	B-GP
nuclear	O
translocation	O
in	O
response	O
to	O
3	O
M3	O
at	O
different	O
time	O
points	O
:	O
1	O
,	O
3	O
and	O
6	O
h	O
,	O
by	O
immunofluorescence	O
analysis	O
.	O

We	O
observed	O
a	O
positive	O
signal	O
for	O
PPARγ	B-GP
in	O
both	O
cytoplasm	O
and	O
nucleus	O
,	O
in	O
untreated	O
cells	O
.	O

We	O
observed	O
an	O
increase	O
of	O
PPARγ	B-GP
nuclear	O
staining	O
in	O
cells	O
exposed	O
to	O
3	O
M3	O
,	O
demonstrating	O
a	O
translocation	O
of	O
this	O
transcription	B-GP
factor	I-GP
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
(	O
Fig	O
.	O
4a	O
,	O
b	O
).	O

This	O
observation	O
was	O
also	O
confirmed	O
by	O
the	O
analysis	O
of	O
the	O
extent	O
of	O
PPARγ	B-GP
/	O
DAPI	O
colocalization	O
signals	O
in	O
the	O
nucleus	O
(	O
Fig	O
.	O
4c	O
).	O

(	O
c	O
)	O
Luciferase	B-GP
assay	O
,	O
using	O
the	O
pGL3	O
-(	O
Jwt	O
)	O
3TKLuc	O
reporter	O
construct	O
[	O
31	O
],	O
consistently	O
showed	O
a	O
significant	O
induction	O
of	O
the	O
PPARγ	B-GP
transcriptional	O
activity	O
after	O
24	O
h	O
of	O
3	O
M3	O
treatment	O
(	O
Fig	O
.	O
4d	O
).	O
Fig	O
.	O
4Analysis	O
of	O
PPARγ	B-GP
translocation	O
into	O
the	O
nucleus	O
and	O
activity	O
in	O
response	O
to	O
3	O
M3	O
exposure	O
.	O

(	O
a	O
,	O
b	O
,	O
c	O
)	O
Immunofluorescence	O
analysis	O
of	O
PPARγ	B-GP
localization	O
in	O
untreated	O
cells	O
(	O
A	O
-	O
C	O
,	O
G	O
-	O
I	O
)	O
and	O
in	O
cells	O
treated	O
with	O
15	O
μM	O
3	O
M3	O
for	O
3	O
h	O
(	O
D	O
-	O
F	O
,	O
J	O
-	O
L	O
).	O

Immunolabeling	O
with	O
anti	O
-	O
PPARγ	B-GP
antibody	O
and	O
nuclear	O
staining	O
with	O
DAPI	O
.	O

Scale	O
bar	O
:	O
20	O
μM	O
.	O

(	O
c	O
)	O
Quantitative	O
analysis	O
of	O
the	O
PPARγ	B-GP
/	O
DAPI	O
colocalization	O
signal	O
in	O
the	O
nucleus	O
.	O

Results	O
are	O
express	O
as	O
fold	O
increase	O
of	O
colocalization	O
signal	O
with	O
respect	O
to	O
the	O
values	O
obtained	O
in	O
untreated	O
cells	O
and	O
are	O
reported	O
as	O
mean	O
value	O
±	O
SD	O
(%)	O
(*	O
p	O
<	O
0	O
.	O
01	O
).	O

(	O
d	O
)	O
Transcriptional	O
activity	O
of	O
PPARγ	B-GP
(	O
fold	O
change	O
)	O
by	O
luciferase	B-GP
activity	O
assay	O
in	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
.	O

Cells	O
were	O
transfected	O
with	O
pGL3	O
-(	O
Jwt	O
)	O
3TKLuc	O
reporter	O
construct	O
.	O

After	O
24	O
h	O
of	O
transfection	O
,	O
cells	O
were	O
treated	O
with	O
15	O
μM	O
3	O
M3	O
.	O

The	O
measurement	O
of	O
luciferase	B-GP
activity	O
was	O
carried	O
out	O
24	O
h	O
after	O
treatment	O
.	O

The	O
variability	O
of	O
transfection	O
was	O
normalized	O
with	O
β	B-GP
-	I-GP
Gal	I-GP
activity	O
.	O

The	O
results	O
were	O
expressed	O
as	O
fold	O
change	O
with	O
respect	O
to	O
untreated	O
cells	O
.	O

Data	O
are	O
mean	O
values	O
±	O
SD	O
of	O
three	O
independent	O
experiments	O
performed	O
in	O
triplicate	O
.	O
*	O
p	O
<	O
0	O
.	O
01	O
(	O
vs	O
untreated	O
cells	O
)	O

Then	O
,	O
we	O
tried	O
to	O
understand	O
whether	O
the	O
treatment	O
with	O
3	O
M3	O
was	O
able	O
to	O
reproduce	O
the	O
effects	O
of	O
αMSH	B-GP
on	O
cell	O
number	O
and	O
proliferation	O
in	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
cells	O
.	O

The	O
exposure	O
to	O
3	O
M3	O
for	O
24	O
and	O
48	O
h	O
determined	O
a	O
significant	O
decrease	O
of	O
cell	O
number	O
in	O
both	O
melanoma	B-DS
cell	O
lines	O
.	O

This	O
decrease	O
was	O
fully	O
comparable	O
to	O
that	O
promoted	O
by	O
αMSH	B-GP
(	O
Fig	O
.	O
5a	O
).	O

Furthermore	O
,	O
the	O
exposure	O
to	O
3	O
M3	O
for	O
24	O
h	O
,	O
promoted	O
a	O
significant	O
increase	O
in	O
the	O
proportion	O
of	O
cells	O
distributed	O
in	O
the	O
G0	O
/	O
G1	O
phase	O
of	O
cell	O
cycle	O
(	O
Fig	O
.	O
5b	O
).	O

The	O
expression	O
level	O
of	O
p27	B-GP
was	O
already	O
significantly	O
induced	O
after	O
4	O
h	O
of	O
treatment	O
with	O
3	O
M3	O
,	O
in	O
both	O
melanoma	B-DS
cell	O
lines	O
.	O

The	O
same	O
treatment	O
determined	O
a	O
significant	O
up	O
-	O
regulation	O
of	O
p21	B-GP
protein	O
expression	O
after	O
48	O
h	O
.	O

Consistently	O
,	O
3	O
M3	O
exposure	O
significantly	O
down	O
-	O
regulated	O
the	O
levels	O
of	O
both	O
cyclin	B-GP
D1	I-GP
and	O
cyclin	B-GP
E	I-GP
after	O
6	O
h	O
(	O
Fig	O
.	O
5c	O
).	O

Thus	O
,	O
the	O
direct	O
induction	O
of	O
the	O
pathway	O
by	O
3	O
M3	O
is	O
able	O
to	O
reproduce	O
the	O
αMSH	B-GP
mediated	O
effect	O
on	O
proliferation	O
in	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
melanoma	B-DS
cell	O
lines	O
.	O
Fig	O
.	O
5The	O
direct	O
induction	O
of	O
the	O
pathway	O
by	O
3	O
M3	O
mimics	O
the	O
αMSH	B-GP
mediated	O
effect	O
on	O
proliferation	O
in	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
melanoma	B-DS
cell	O
lines	O
.	O
a	O
Analysis	O
of	O
cell	O
number	O
performed	O
on	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
,	O
after	O
treatment	O
with	O
15	O
μM	O
3	O
m3	O
for	O
24	O
and	O
48	O
h	O
.	O

Cell	O
number	O
was	O
expressed	O
as	O
a	O
percent	O
variation	O
in	O
comparison	O
with	O
the	O
value	O
of	O
untreated	O
control	O
cells	O
.	O

Data	O
are	O
mean	O
values	O
±	O
SD	O
of	O
three	O
independent	O
experiments	O
performed	O
in	O
triplicate	O
.	O
*	O
p	O
<	O
0	O
.	O
01	O
and	O
**	O
p	O
<	O
0	O
.	O
001	O
(	O
vs	O
untreated	O
cells	O
).	O
b	O
Cell	O
-	O
cycle	O
distribution	O
evaluated	O
by	O
flow	O
cytometric	O
analysis	O
on	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
,	O
after	O
treatment	O
for	O
24	O
h	O
with	O
15	O
μM	O
3	O
m3	O
.	O

The	O
bar	O
graph	O
shows	O
the	O
distribution	O
of	O
cells	O
among	O
the	O
different	O
phases	O
of	O
the	O
cell	O
cycle	O
.	O

Data	O
are	O
mean	O
values	O
±	O
SD	O
of	O
three	O
independent	O
experiments	O
performed	O
in	O
duplicate	O
.	O
*	O
p	O
<	O
0	O
.	O
01	O
(	O
vs	O
untreated	O
cells	O
).	O
c	O
Western	O
blot	O
analysis	O
of	O
p27	B-GP
(	O
4	O
h	O
),	O
p21	B-GP
(	O
48	O
h	O
),	O
cyclin	B-GP
D1	I-GP
and	O
cyclin	B-GP
E	I-GP
(	O
6	O
h	O
)	O
protein	O
expression	O
on	O
cell	O
lysate	O
of	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
,	O
treated	O
with	O
15	O
μM	O
3	O
m3	O
.	O

GAPDH	B-GP
or	O
HSP70	B-GP
were	O
used	O
as	O
an	O
equal	O
loading	O
control	O
.	O

Results	O
refer	O
to	O
three	O
independent	O
experiments	O
.	O

Representative	O
blots	O
are	O
shown	O
.	O

Densitometric	O
scanning	O
of	O
band	O
intensities	O
was	O
performed	O
to	O
quantify	O
the	O
change	O
of	O
protein	O
expression	O
(	O
control	O
value	O
taken	O
as	O
one	O
fold	O
in	O
each	O
case	O
).	O
*	O
p	O
<	O
0	O
,	O
01	O
(	O
vs	O
untreated	O
cells	O
)	O

The	O
PPARγ	B-GP
acts	O
as	O
an	O
effector	O
element	O
in	O
determining	O
the	O
reduction	O
of	O
cell	O
number	O
induced	O
by	O
the	O
activation	O
of	O
PI	O
(	O
4	O
,	O
5	O
)	O
P2	O
/	O
PLC	B-GP
pathway	O
in	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
melanoma	B-DS
cell	O
lines	O

In	O
order	O
to	O
strengthen	O
the	O
role	O
of	O
PPARγ	B-GP
in	O
mediating	O
the	O
reduction	O
in	O
the	O
number	O
of	O
cells	O
induced	O
by	O
the	O
stimulation	O
of	O
“	O
PI	O
(	O
4	O
,	O
5	O
)	O
P2	O
/	O
PLC	B-GP
pathway	O
”,	O
both	O
B16	O
-	O
F10	O
cells	O
and	O
Mel	O
13	O
human	B-OG
melanoma	B-DS
cells	O
were	O
stimulated	O
with	O
3	O
M3	O
,	O
for	O
24	O
and	O
48	O
h	O
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
GW9662	O
,	O
as	O
an	O
inhibitor	O
of	O
PPARγ	B-GP
[	O
29	O
].	O

This	O
pattern	O
of	O
stimulation	O
was	O
compared	O
to	O
that	O
represented	O
by	O
cells	O
treated	O
with	O
αMSH	B-GP
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
GW9662	O
.	O

In	O
both	O
cell	O
lines	O
,	O
the	O
exposure	O
of	O
cells	O
to	O
3	O
M3	O
or	O
αMSH	B-GP
led	O
to	O
a	O
significant	O
decrease	O
of	O
number	O
of	O
cells	O
.	O

Whereas	O
,	O
the	O
same	O
treatments	O
,	O
in	O
the	O
presence	O
of	O
GW9662	O
,	O
significantly	O
hindered	O
the	O
effectiveness	O
of	O
3	O
M3	O
or	O
αMSH	B-GP
in	O
reducing	O
the	O
cell	O
number	O
after	O
24	O
h	O
of	O
treatment	O
(	O
Fig	O
.	O
6a	O
).	O

Consistently	O
with	O
these	O
results	O
,	O
the	O
exposure	O
of	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
for	O
24	O
h	O
to	O
3	O
M3	O
or	O
αMSH	B-GP
,	O
was	O
able	O
to	O
promote	O
a	O
significant	O
increase	O
in	O
the	O
proportion	O
of	O
cells	O
distributed	O
in	O
the	O
G0	O
/	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
and	O
the	O
co	O
-	O
treatment	O
with	O
GW9962	O
counteracted	O
the	O
effects	O
of	O
both	O
the	O
agents	O
(	O
Fig	O
.	O
6b	O
).	O

Accordingly	O
,	O
the	O
inhibition	O
of	O
PPARγ	B-GP
by	O
GW9662	O
reverted	O
the	O
effects	O
on	O
cell	O
cycle	O
modulators	O
(	O
p27	B-GP
,	O
p21	B-GP
,	O
Cyclin	B-GP
D1	I-GP
and	O
cyclin	B-GP
E	I-GP
)	O
promoted	O
by	O
αMSH	B-GP
in	O
both	O
melanoma	B-DS
cell	O
lines	O
(	O
Fig	O
.	O
6c	O
).	O

All	O
together	O
,	O
these	O
results	O
underline	O
the	O
key	O
role	O
of	O
PPARγ	B-GP
in	O
mediating	O
the	O
αMSH	B-GP
dependent	O
effect	O
on	O
proliferation	O
slow	O
down	O
.	O
Fig	O
.	O
6The	O
PPARγ	B-GP
acts	O
as	O
an	O
effector	O
element	O
in	O
determining	O
the	O
reduction	O
of	O
cell	O
number	O
induced	O
by	O
the	O
activation	O
of	O
PI	O
(	O
4	O
,	O
5	O
)	O
P2	O
/	O
PLC	B-GP
pathway	O
in	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
melanoma	B-DS
cell	O
lines	O
.	O
a	O
Analysis	O
of	O
cell	O
number	O
performed	O
on	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
,	O
after	O
treatment	O
for	O
24	O
and	O
48	O
h	O
with	O
15	O
μM	O
3	O
m3	O
or	O
10	O
−	O
7	O
M	O
αMSH	B-GP
in	O
the	O
presence	O
or	O
absence	O
of	O
3	O
μM	O
GW9662	O
.	O

In	O
the	O
combined	O
treatment	O
αMSH	B-GP
/	O
GW9662	O
or	O
3	O
m3	O
/	O
GW9662	O
,	O
cells	O
underwent	O
a	O
pre	O
-	O
treatment	O
with	O
GW9662	O
for	O
1	O
h	O
.	O

Cell	O
number	O
was	O
expressed	O
as	O
a	O
percent	O
variation	O
in	O
comparison	O
to	O
the	O
value	O
of	O
untreated	O
control	O
cells	O
.	O

Data	O
are	O
mean	O
values	O
±	O
SD	O
of	O
three	O
independent	O
experiments	O
performed	O
in	O
triplicate	O
.	O
*	O
p	O
<	O
0	O
.	O
01	O
and	O
**	O
p	O
<	O
0	O
.	O
001	O
(	O
vs	O
untreated	O
cells	O
);	O
$	O
p	O
<	O
0	O
.	O
01	O
(	O
vs	O
3	O
m3	O
-	O
treated	O
cells	O
);	O
§	O
p	O
<	O
0	O
.	O
01	O
(	O
vs	O
αMSH	B-GP
-	O
treated	O
cells	O
).	O
b	O
Cell	O
-	O
cycle	O
distribution	O
evaluated	O
by	O
flow	O
cytometric	O
analysis	O
on	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
,	O
after	O
treatment	O
for	O
24	O
h	O
with	O
15	O
μM	O
3	O
m3	O
or	O
10	O
−	O
7	O
M	O
αMSH	B-GP
in	O
the	O
presence	O
or	O
absence	O
of	O
3	O
μM	O
GW9662	O
.	O

In	O
the	O
combined	O
treatment	O
αMSH	B-GP
/	O
GW9662	O
or	O
3	O
M3	O
/	O
GW9662	O
,	O
cells	O
underwent	O
a	O
pre	O
-	O
treatment	O
with	O
GW9662	O
for	O
1	O
h	O
.	O

The	O
bar	O
graph	O
shows	O
the	O
distribution	O
of	O
cells	O
among	O
the	O
different	O
phases	O
of	O
the	O
cell	O
cycle	O
.	O

Data	O
are	O
mean	O
values	O
±	O
SD	O
of	O
three	O
independent	O
experiments	O
performed	O
in	O
duplicate	O
.	O
*	O
p	O
<	O
0	O
.	O
01	O
(	O
vs	O
untreated	O
cells	O
);	O
$	O
p	O
<	O
0	O
.	O
01	O
(	O
vs	O
3	O
m3	O
-	O
treated	O
cells	O
);	O
§	O
p	O
<	O
0	O
.	O
01	O
(	O
vs	O
αMSH	B-GP
-	O
treated	O
cells	O
).	O
c	O
Western	O
blot	O
analysis	O
of	O
p27	B-GP
(	O
4	O
h	O
),	O
p21	B-GP
(	O
48	O
h	O
),	O
cyclin	B-GP
D1	I-GP
and	O
cyclin	B-GP
E	I-GP
(	O
6	O
h	O
)	O
protein	O
expression	O
on	O
cell	O
lysate	O
of	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
,	O
treated	O
with	O
10	O
−	O
7	O
M	O
αMSH	B-GP
in	O
the	O
presence	O
or	O
absence	O
of	O
3	O
μM	O
GW9662	O
.	O

In	O
the	O
combined	O
treatment	O
αMSH	B-GP
/	O
GW9662	O
,	O
cells	O
underwent	O
a	O
pre	O
-	O
treatment	O
with	O
GW9662	O
for	O
1	O
h	O
.	O

GAPDH	B-GP
or	O
HSP70	B-GP
were	O
used	O
as	O
an	O
equal	O
loading	O
control	O
.	O

Results	O
refer	O
to	O
three	O
independent	O
experiments	O
.	O

Representative	O
blots	O
are	O
shown	O
.	O

Densitometric	O
scanning	O
of	O
band	O
intensities	O
was	O
performed	O
to	O
quantify	O
the	O
change	O
of	O
protein	O
expression	O
(	O
control	O
value	O
taken	O
as	O
one	O
fold	O
in	O
each	O
case	O
).	O
*	O
p	O
<	O
0	O
,	O
01	O
(	O
vs	O
untreated	O
cells	O
),	O
$	O
p	O
<	O
0	O
,	O
01	O
(	O
vs	O
αMSH	B-GP
-	O
treated	O
cells	O
)	O

Discussion	O

MC1R	B-GP
is	O
primarily	O
located	O
on	O
the	O
surface	O
of	O
melanocytes	O
and	O
plays	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
normal	O
pigmentation	O
.	O

However	O
,	O
as	O
a	O
member	O
of	O
“	O
G	B-GP
protein	I-GP
-	I-GP
coupled	I-GP
receptors	I-GP
”	O
family	O
,	O
MC1R	B-GP
exerts	O
a	O
role	O
in	O
the	O
control	O
of	O
proliferation	O
.	O

Studies	O
on	O
this	O
topic	O
are	O
sporadic	O
ad	O
provide	O
evidence	O
that	O
the	O
activated	O
receptor	O
appears	O
to	O
be	O
influenced	O
by	O
the	O
physiological	O
state	O
and	O
/	O
or	O
transformation	O
.	O

This	O
study	O
tried	O
to	O
confirm	O
the	O
different	O
proliferative	O
behavior	O
,	O
in	O
response	O
to	O
MSH	B-GP
,	O
in	O
healthy	O
and	O
then	O
in	O
melanoma	B-DS
condition	O
and	O
to	O
deepen	O
the	O
knowledge	O
of	O
the	O
molecular	O
basis	O
responsible	O
for	O
the	O
down	O
-	O
proliferative	O
response	O
of	O
melanoma	B-DS
cells	O
after	O
exposure	O
to	O
αMSH	B-GP
.	O

The	O
first	O
series	O
of	O
experiments	O
evidenced	O
that	O
while	O
in	O
primary	O
cultures	O
of	O
human	B-OG
melanocytes	O
the	O
αMSH	B-GP
acted	O
as	O
a	O
mitogenic	O
agent	O
[	O
1	O
,	O
3	O
],	O
in	O
Mel	O
13	O
human	B-OG
melanoma	B-DS
cell	O
line	O
and	O
in	O
the	O
B16	O
-	O
F10	O
murine	O
melanoma	B-DS
cell	O
line	O
,	O
this	O
hormone	O
did	O
not	O
exert	O
the	O
same	O
effect	O
.	O

In	O
the	O
case	O
of	O
melanocyte	O
cultures	O
,	O
the	O
hyper	O
-	O
proliferation	O
in	O
response	O
to	O
αMSH	B-GP
stimulus	O
can	O
be	O
found	O
in	O
literature	O
[	O
1	O
,	O
3	O
,	O
15	O
–	O
17	O
].	O

This	O
kind	O
of	O
response	O
contravenes	O
one	O
of	O
the	O
axioms	O
of	O
cell	O
biology	O
,	O
which	O
associates	O
the	O
differentiation	O
process	O
with	O
a	O
decrease	O
in	O
proliferation	O
rates	O
.	O

This	O
proliferative	O
reduction	O
is	O
usually	O
considered	O
necessary	O
,	O
in	O
order	O
to	O
store	O
energy	O
,	O
which	O
can	O
be	O
employed	O
to	O
accomplish	O
differentiation	O
itself	O
.	O

Whereas	O
,	O
in	O
the	O
case	O
of	O
melanocytes	O
,	O
the	O
hyper	O
-	O
proliferative	O
response	O
to	O
the	O
hormone	O
may	O
be	O
interpreted	O
as	O
a	O
necessity	O
for	O
melanocytes	O
to	O
increase	O
their	O
number	O
,	O
to	O
produce	O
more	O
melanin	O
and	O
better	O
protect	O
the	O
skin	O
from	O
ultraviolet	O
radiation	O
.	O

On	O
the	O
other	O
hand	O
,	O
melanoma	B-DS
cells	O
have	O
a	O
basal	O
sustained	O
rate	O
of	O
proliferation	O
,	O
and	O
our	O
results	O
highlight	O
the	O
ability	O
of	O
αMSH	B-GP
to	O
trigger	O
a	O
mechanism	O
capable	O
of	O
counteracting	O
this	O
biological	O
feature	O
.	O

In	O
fact	O
,	O
the	O
slow	O
down	O
of	O
proliferation	O
that	O
we	O
previously	O
described	O
in	O
B16	O
-	O
F10	O
[	O
7	O
],	O
was	O
confirmed	O
on	O
the	O
Mel	O
13	O
human	B-OG
melanoma	B-DS
cell	O
line	O
.	O

Thus	O
,	O
the	O
effect	O
promoted	O
by	O
αMSH	B-GP
on	O
proliferation	O
seems	O
to	O
be	O
associated	O
with	O
the	O
pathological	O
state	O
and	O
not	O
with	O
the	O
animal	O
species	O
which	O
the	O
culture	O
derives	O
from	O
.	O

In	O
order	O
to	O
find	O
the	O
pathway	O
driving	O
the	O
αMSH	B-GP
mediated	O
effects	O
on	O
proliferation	O
in	O
our	O
cell	O
lines	O
,	O
we	O
treated	O
cells	O
with	O
FSK	O
,	O
which	O
is	O
able	O
to	O
by	O
-	O
pass	O
the	O
MC1R	B-GP
receptor	I-GP
and	O
to	O
stimulate	O
the	O
overall	O
cAMP	O
/	O
PKA	B-GP
cell	O
potential	O
[	O
8	O
].	O

It	O
is	O
noteworthy	O
that	O
in	O
our	O
cell	O
lines	O
FKS	O
determined	O
uniquely	O
a	O
hyper	O
-	O
proliferative	O
response	O
,	O
both	O
in	O
NHMs	O
and	O
in	O
melanoma	B-DS
cell	O
lines	O
.	O

This	O
result	O
,	O
which	O
requires	O
in	O
depth	O
study	O
,	O
may	O
be	O
ascribed	O
to	O
a	O
CREB	B-GP
mediated	O
mechanism	O
.	O

In	O
fact	O
,	O
this	O
transcription	B-GP
factor	I-GP
,	O
one	O
of	O
the	O
major	O
PKA	B-GP
substrates	O
,	O
binds	O
to	O
the	O
promoter	O
of	O
cell	O
cycle	O
regulators	O
,	O
such	O
as	O
cyclin	B-GP
D1	I-GP
,	O
activating	O
their	O
transcription	O
[	O
32	O
].	O

Furthermore	O
,	O
the	O
comparison	O
between	O
the	O
response	O
of	O
melanocytes	O
and	O
transformed	O
cells	O
to	O
FSK	O
showed	O
a	O
quantitative	O
rather	O
than	O
a	O
qualitative	O
difference	O
.	O

The	O
hyper	O
-	O
proliferative	O
response	O
to	O
FSK	O
appeared	O
more	O
marked	O
in	O
primary	O
cultures	O
of	O
melanocytes	O
than	O
in	O
the	O
transformed	O
condition	O
.	O

In	O
fact	O
,	O
PKA	B-GP
is	O
active	O
in	O
basal	O
conditions	O
and	O
supported	O
the	O
rate	O
of	O
basal	O
proliferation	O
,	O
in	O
melanoma	B-DS
cells	O
[	O
33	O
].	O

Therefore	O
PKA	B-GP
activity	O
cannot	O
be	O
further	O
enhanced	O
by	O
additional	O
stimulation	O
,	O
such	O
as	O
that	O
due	O
to	O
FSK	O
.	O

To	O
define	O
an	O
alternative	O
pathway	O
which	O
could	O
justify	O
the	O
proliferation	O
slow	O
down	O
induced	O
by	O
αMSH	B-GP
in	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
melanoma	B-DS
cell	O
lines	O
,	O
our	O
attention	O
focused	O
on	O
the	O
PI	O
(	O
4	O
,	O
5	O
)	O
P2	O
/	O
PLC	B-GP
pathway	O
.	O

This	O
lipid	O
involving	O
pathway	O
was	O
in	O
fact	O
promoted	O
in	O
response	O
to	O
αMSH	B-GP
exposure	O
in	O
B16	O
-	O
F10	O
and	O
was	O
directly	O
involved	O
in	O
the	O
PPARγ	B-GP
activation	O
[	O
7	O
].	O

When	O
the	O
PPARγ	B-GP
transcription	B-GP
factor	I-GP
is	O
activated	O
with	O
lipid	O
ligands	O
or	O
pharmacological	O
activators	O
,	O
it	O
promotes	O
differentiation	O
,	O
anti	O
-	O
inflammatory	O
effects	O
and	O
a	O
slow	O
down	O
in	O
the	O
rate	O
of	O
cell	O
proliferation	O
.	O

For	O
this	O
reasons	O
it	O
is	O
considered	O
a	O
good	O
candidate	O
in	O
the	O
creation	O
of	O
possible	O
innovative	O
biological	O
anticancer	O
therapies	O
[	O
11	O
,	O
12	O
,	O
34	O
–	O
36	O
].	O

First	O
,	O
we	O
verified	O
that	O
the	O
direct	O
stimulation	O
of	O
PLC	B-GP
was	O
able	O
to	O
promote	O
PPARγ	B-GP
translocation	O
into	O
the	O
nucleus	O
as	O
an	O
active	O
transcription	B-GP
factor	I-GP
,	O
on	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
cell	O
line	O
.	O

Then	O
we	O
found	O
that	O
the	O
direct	O
induction	O
of	O
the	O
PI	O
(	O
4	O
,	O
5	O
)	O
P2	O
/	O
PLC	B-GP
pathway	O
was	O
able	O
to	O
reproduce	O
the	O
αMSH	B-GP
mediated	O
effects	O
on	O
proliferation	O
.	O

Subsequent	O
experiments	O
,	O
carried	O
out	O
by	O
stimulating	O
the	O
cells	O
with	O
3	O
M3	O
(	O
or	O
αMSH	B-GP
),	O
after	O
inhibition	O
of	O
PPARγ	B-GP
with	O
GW9662	O
,	O
led	O
to	O
similar	O
results	O
in	O
the	O
two	O
conditions	O
,	O
thereby	O
highlighting	O
the	O
role	O
of	O
PPARγ	B-GP
as	O
an	O
effector	O
element	O
(	O
triggered	O
by	O
the	O
active	O
PI	O
(	O
4	O
,	O
5	O
)	O
P2	O
/	O
PLC	B-GP
pathway	O
)	O
capable	O
of	O
mediating	O
the	O
phenomenon	O
.	O

For	O
what	O
concerns	O
the	O
molecular	O
nature	O
of	O
the	O
proliferation	O
slow	O
down	O
consequent	O
to	O
the	O
activation	O
of	O
the	O
αMSH	B-GP
/	O
PPARγ	B-GP
connection	O
,	O
we	O
showed	O
that	O
it	O
is	O
due	O
to	O
cell	O
cycle	O
withdrawal	O
.	O

Cell	O
cycle	O
progression	O
is	O
coordinated	O
by	O
the	O
expression	O
and	O
activity	O
of	O
key	O
regulators	O
,	O
such	O
as	O
cyclin	B-GP
dependent	I-GP
kinase	I-GP
(	O
CDKs	B-GP
)	O
and	O
cyclins	B-GP
,	O
including	O
cyclin	B-GP
D	I-GP
,	O
cyclin	B-GP
E	I-GP
[	O
21	O
,	O
22	O
]	O
and	O
CDKs	B-GP
-	O
inhibitors	O
,	O
like	O
p21	B-GP
and	O
p27	B-GP
[	O
24	O
,	O
25	O
].	O

Our	O
analyses	O
showed	O
that	O
the	O
G0	O
/	O
G1	O
arrest	O
,	O
mediated	O
by	O
the	O
αMSH	B-GP
/	O
PPARγ	B-GP
axis	O
,	O
is	O
associated	O
with	O
an	O
up	O
-	O
regulation	O
of	O
p21	B-GP
and	O
p27	B-GP
and	O
down	O
-	O
modulation	O
of	O
cyclin	B-GP
D1	I-GP
and	O
cyclin	B-GP
E	I-GP
.	O

These	O
results	O
are	O
in	O
agreement	O
with	O
previous	O
reports	O
,	O
employing	O
natural	O
and	O
synthetic	O
PPARγ	B-GP
agonists	O
[	O
34	O
,	O
37	O
–	O
39	O
].	O

p27	B-GP
and	O
p21	B-GP
are	O
transcriptional	O
repressors	O
of	O
the	O
same	O
genes	O
and	O
associate	O
with	O
the	O
same	O
multi	O
-	O
protein	O
complexes	O
.	O

It	O
has	O
recently	O
been	O
demonstrated	O
that	O
p27	B-GP
and	O
p21	B-GP
collaborate	O
in	O
a	O
sequential	O
manner	O
in	O
gene	O
repression	O
during	O
G1	O
phase	O
[	O
25	O
].	O

The	O
peaks	O
of	O
expression	O
of	O
p27	B-GP
and	O
p21	B-GP
,	O
which	O
we	O
have	O
observed	O
at	O
different	O
times	O
(	O
4	O
h	O
for	O
p27	B-GP
and	O
48	O
h	O
for	O
p21	B-GP
),	O
could	O
reflect	O
their	O
sequential	O
function	O
over	O
time	O
.	O

Conclusion	O

This	O
work	O
dealt	O
with	O
the	O
analysis	O
of	O
the	O
αMSH	B-GP
/	O
MC1R	B-GP
interaction	O
for	O
its	O
ability	O
to	O
influence	O
proliferation	O
in	O
healthy	O
melanocytes	O
and	O
in	O
melanoma	B-DS
cells	O
,	O
an	O
aspect	O
that	O
has	O
already	O
been	O
investigated	O
in	O
the	O
past	O
in	O
preliminary	O
and	O
sporadic	O
studies	O
.	O

This	O
study	O
attributes	O
an	O
opposite	O
functional	O
significance	O
to	O
the	O
cAMP	O
/	O
PKA	B-GP
pathway	O
and	O
to	O
the	O
PLC	B-GP
/	O
PPARγ	B-GP
axis	O
,	O
respectively	O
,	O
in	O
the	O
control	O
of	O
proliferation	O
,	O
giving	O
the	O
former	O
a	O
role	O
in	O
stimulating	O
hyper	O
-	O
proliferation	O
and	O
the	O
latter	O
a	O
function	O
in	O
promoting	O
down	O
-	O
proliferation	O
.	O

This	O
evidence	O
attributes	O
a	O
dynamic	O
role	O
to	O
the	O
activated	O
MC1R	B-GP
which	O
is	O
able	O
to	O
transducer	O
effects	O
on	O
proliferation	O
through	O
these	O
pathways	O
.	O

The	O
αMSH	B-GP
dependent	O
cAMP	O
/	O
PKA	B-GP
pathway	O
activation	O
favors	O
hyper	O
-	O
proliferation	O
and	O
ensures	O
the	O
promotion	O
of	O
melanogenesis	O
,	O
in	O
healthy	O
melanocytes	O
,	O
which	O
are	O
poorly	O
represented	O
within	O
the	O
skin	O
.	O

In	O
melanoma	B-DS
cells	O
,	O
in	O
which	O
the	O
cAMP	O
/	O
PKA	B-GP
pathway	O
is	O
already	O
active	O
and	O
correlates	O
with	O
their	O
basal	O
rate	O
of	O
proliferation	O
,	O
the	O
PLC	B-GP
-	O
PPARγ	B-GP
pathway	O
emerged	O
with	O
particular	O
emphasis	O
,	O
showing	O
it	O
exerts	O
an	O
opposite	O
effect	O
on	O
proliferation	O
.	O

The	O
PLC	B-GP
/	O
PPARγ	B-GP
connection	O
has	O
both	O
an	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
cancer	B-DS
potential	O
.	O

In	O
fact	O
,	O
acting	O
as	O
a	O
transcription	B-GP
factor	I-GP
,	O
PPARγ	B-GP
,	O
is	O
capable	O
of	O
enhancing	O
both	O
these	O
activities	O
.	O

In	O
summary	O
,	O
these	O
results	O
provide	O
information	O
on	O
the	O
biology	O
of	O
MC1R	B-GP
and	O
the	O
ability	O
of	O
this	O
receptor	O
to	O
control	O
extra	O
-	O
pigmentary	O
functions	O
.	O

The	O
PLC	B-GP
/	O
PPARγ	B-GP
axis	O
,	O
inside	O
the	O
MC1R	B-GP
transduction	O
machinery	O
,	O
could	O
represent	O
an	O
element	O
which	O
potentially	O
offers	O
new	O
therapeutic	O
approaches	O
for	O
melanoma	B-DS
.	O

Additional	O
files	O

Additional	O
file	O
1	O
:	O
Supplementary	O
Materials	O
and	O
Methods	O
.	O

(	O
DOCX	O
11	O
kb	O
)	O
Additional	O
file	O
2	O
:	O
Figure	O
S1	O
.	O
Expression	O
and	O
functionality	O
of	O
MC1R	B-GP
in	O
NHMs	O
,	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
melanoma	B-DS
cell	O
lines	O
(	O
a	O
)	O
Expression	O
of	O
MC1R	B-GP
mRNA	O
evaluated	O
by	O
quantitative	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

Values	O
are	O
normalized	O
against	O
the	O
expression	O
of	O
β	B-GP
-	I-GP
actin	I-GP
.	O

The	O
values	O
reported	O
represent	O
means	O
±	O
SD	O
of	O
three	O
independent	O
experiments	O
performed	O
in	O
triplicate	O
.	O

(	O
b	O
)	O
Immunofluorescence	O
analysis	O
of	O
MC1	B-GP
-	I-GP
R	I-GP
in	O
NHM	O
1	O
,	O
NHM	O
2	O
,	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
.	O

Nuclear	O
staining	O
with	O
DAPI	O
.	O

Scale	O
bar	O
:	O
20	O
μM	O
.	O

(	O
c	O
)	O
Western	O
blot	O
analysis	O
of	O
tyrosinase	B-GP
protein	O
expression	O
on	O
cell	O
lysate	O
of	O
NHM1	O
and	O
NHM2	O
primary	O
cultures	O
of	O
human	B-OG
melanocytes	O
,	O
B16	O
-	O
F10	O
and	O
Mel	O
13	O
,	O
treated	O
with	O
10	O
−	O
7	O
M	O
αMSH	B-GP
for	O
72	O
h	O
in	O
NHM	O
1	O
and	O
NHM	O
2	O
,	O
for	O
24	O
h	O
in	O
B16	O
-	O
F10	O
cells	O
and	O
for	O
48	O
h	O
in	O
Mel	O
13	O
,	O
respectively	O
.	O

GAPDH	B-GP
was	O
used	O
as	O
an	O
equal	O
loading	O
control	O
.	O

Results	O
refer	O
to	O
three	O
independent	O
experiments	O
.	O

Representative	O
blots	O
are	O
shown	O
.	O

Densitometric	O
scanning	O
of	O
band	O
intensities	O
was	O
performed	O
to	O
quantify	O
the	O
change	O
of	O
protein	O
expression	O
(	O
control	O
value	O
taken	O
as	O
one	O
fold	O
in	O
each	O
case	O
).	O
*	O
p	O
<	O
0	O
.	O
01	O
(	O
vs	O
untreated	O
cells	O
).	O

(	O
PDF	O
9380	O
kb	O
)	O
Additional	O
file	O
3	O
:	O
Figure	O
S2	O
.	O
Analysis	O
of	O
3	O
M3	O
mediated	O
calcium	O
fluxes	O
in	O
(	O
a	O
)	O
B16	O
-	O
F10	O
cells	O
and	O
(	O
b	O
)	O
Mel	O
13	O
The	O
profile	O
of	O
the	O
intra	O
-	O
cytoplasm	O
calcium	O
fluxes	O
in	O
response	O
to	O
stimulation	O
with	O
15	O
μM	O
3	O
M3	O
was	O
obtained	O
using	O
a	O
fluorimetric	O
detection	O
.	O

The	O
analysis	O
was	O
followed	O
for	O
30	O
min	O
by	O
monitoring	O
calcium	O
fluxes	O
each	O
minute	O
.	O

The	O
calcium	O
fluxes	O
promoted	O
by	O
3	O
M3	O
were	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
than	O
the	O
baseline	O
of	O
untreated	O
cells	O
(	O
100	O
%).	O

Results	O
represent	O
the	O
mean	O
±	O
SD	O
of	O
six	O
experiments	O
performed	O
in	O
exaplicate	O
and	O
are	O
expressed	O
as	O
the	O
percentage	O
of	O
fluo	O
-	O
3	O
fluorescence	O
with	O
respect	O
to	O
untreated	O
cells	O
(	O
100	O
%).	O

(	O
PDF	O
525	O
kb	O
)	O

Electronic	O
supplementary	O
material	O

The	O
online	O
version	O
of	O
this	O
article	O
(	O
10	O
.	O
1186	O
/	O
s13046	O
-	O
017	O
-	O
0611	O
-	O
4	O
)	O
contains	O
supplementary	O
material	O
,	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O

